Document:

Exhibit
10.1

 

AMENDED
AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT

 

This
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is made and entered into on May
31, 2019, effective as of April 15, 2019 (the “Effective Date”), by and between HEALTH-RIGHT DISCOVERIES,
INC., a Florida corporation, (the “Company”) and DAVID HOPKINS, an individual (the “Executive”).

 

RECITALS

 

WHEREAS,
the Company and the Executive have heretofore entered into an Executive Employment Agreement, made and entered into on January
10, 2018, effective as of January 1, 2018 (the “Original Employment Agreement”), pursuant to which the Company
employed the Executive; and

 

WHEREAS,
in connection with the Company’s continued employment of the Executive, the Company and the Executive wish to modify and
amend certain terms of the Executive’s employment by the Company and in connection therewith, restate the Original Employment
Agreement in its entirety by entering into this Agreement.

 

AGREEMENT

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

1.          Recitals.          The
above recitals are true and correct and are incorporated herein by reference.

 

2.          Position
and Duties.          The Executive shall serve as Chief Executive Officer and President of the Company reporting to the Company’s
board of directors (the “Board”). The Executive shall perform those services customary to that office and such
other lawful duties that may be reasonably assigned to him from time to time by the Board, provided those duties are consistent
with the Executive’s position and authority. The Executive further agrees to use his best efforts to promote the interests
of the Company and to devote his full business time and energies to the business and affairs of the Company.

 

3.          Term.          The
Company shall continue to employ the Executive and the Executive shall continue to serve the Company, on the terms and conditions
set forth herein, for the period commencing on the Effective Date and expiring on the third anniversary of the Effective Date,
unless sooner terminated as hereinafter set forth (the “Initial Term”). This Agreement shall automatically
renew for successive three (3) year periods (each, a “Renewal Term,” and together with the Initial Term, the
“Term”), provided that the Company’s subsidiaries, CCI Billing, Inc., a Florida corporation and Script
Connection, LLC, a Florida limited liability company (collectively, the “Subsidiaries”), achieve combined Adjusted
EBITDA (as determined by the Company’s accountants from the annual financial statements of the Subsidiaries used in preparing
the Company’s audited annual financial statements) of $3,000,000 for any calendar year during the Initial Term and any Renewal
Term.

 

3.          Compensation
and Related Matters.

 

(a)               
Base Salary.          The Executive’s annual base salary shall be two hundred fifty thousand dollars ($250,000)
(together with any subsequent increases thereto as hereinafter provided, the “Base Salary”). In the event in
any calendar year during the Term, the Subsidiaries achieve combined Adjusted EBITDA (as determined by the Company’s accountants
from the annual financial statements of the Subsidiaries used in preparing the Company’s audited annual financial statements)
of $3,000,000, the Executive’s annual Base Salary shall automatically increase to $300,000 and in the event in any calendar
year during the Term, the Subsidiaries achieve combined Adjusted EBITDA (as determined by the Company’s accountants from
the annual financial statements of the Subsidiaries used in preparing the Company’s audited annual financial statements)
of $3,500,000, the Executive’s annual Base Salary shall automatically increase to $350,000. The Base Salary shall be payable
in accordance with the Company’s normal payroll procedures in effect from time to time. In addition to the foregoing, the
Base Salary may be increased by the Board or its compensation committee (the “Committee”), if any, from time
to time during the Term, but shall be reviewed by the Board or the Committee, if any, at least annually. 

 

     

     

    

 

(b)          Annual Bonus.          During the Term, the Executive may be paid a performance bonus to the extent earned, based on criteria
established by the Board or the Committee from time to time during the Term (the “Bonus”). The amount of any
Bonus and the performance criteria for earning the Bonus, if any for any subsequent fiscal year shall be determined by the Board
or the Committee, in good faith, no later than sixty (60) days after the commencement of the relevant fiscal year. The Executive’s
Bonus for a bonus period shall be determined by the Board or the Committee after the end of the applicable bonus period and be
paid to the Executive in the year following the year to which the Bonus relates when annual bonuses for that year are paid to
other senior executives of the Company generally.

 

(c)          Car Allowance.        During the Term, the Executive shall be entitled to receive a monthly car allowance of $600 (which
may be increased by the Board or the Committee in their sole discretion).

 

(d)          Bonus Plans.          The Executive shall be entitled to participate in all bonus plans, policies, practices and programs
adopted by the Company and applicable generally to other senior executives of the Company, in accordance with the terms of such
plans (if any).

 

(e)          Business Expenses.          The Executive shall be entitled to receive prompt reimbursement for all reasonable business
expenses incurred by him in performing services hereunder, in accordance with the policies and procedures then in effect and established
by the Company for its senior executive officers. 

 

(f)           Directors’ and Officers’ Liability Insurance.          the Effective Date, the Company shall procure. The
Company shall maintain in effect during the term Directors’ and Officers’ Liability Insurance in an amount not less
than $1,000,000, which shall contain customary coverage for the Executive, as long as such coverage can be secured at commercially
reasonable cost. 

 

(g)          Other Benefits.          The Executive shall be eligible to participate in the employee benefit plans currently and hereafter
maintained by the Company of general applicability to other senior executives of the Company, including, without limitation, the
Company’s group medical, dental, vision, disability, life insurance, and flexible-spending account plans. 

 

(h)          Vacation and Personal Days.          The Executive shall be entitled to four weeks of vacation during the first year of
the Term and five (5) weeks of vacation during each subsequent year of the Term, to be taken at such times as the Executive may
select, and the affairs of the Company may permit. The Executive shall also be entitled to five (5) personal days during each
year of the Term or such greater number of personal days as may be afforded employees generally under the Company’s policy
in effect from time to time during the Term. Vacation and personal days shall be taken by the Executive without loss of compensation
or other benefits to which he is entitled under this Agreement. Unused vacation or personal days at the end of each year of the
Term shall be paid out to the Executive.

 

(i)           Withholding.           All amounts payable to the Executive under this Section 3 shall be subject to all required
federal, state and local withholding, payroll and insurance taxes.

 

(j)           Board Discretion.          Nothing in this Section 3 shall obligate the Board to implement any particular benefit
plan or prevent the Board from amending or terminating any benefit plan implemented. 

 

     

     

    

 

1.            Termination.          The Executive’s employment may be terminated and this Agreement terminated under the following
circumstances:

 

(a)                
Death.          The Executive’s employment hereunder shall terminate upon his death.

 

(b)                
 Disability.          The Company may terminate the Executive’s employment if the Executive becomes subject to a
Disability. For purposes of this Agreement, “Disability” means the Executive is unable to perform the essential
functions of his position as President, with or without a reasonable accommodation, for a period of one hundred twenty (120) consecutive
calendar days or one hundred eighty (180) non-consecutive calendar days within any rolling twelve (12) month period because of
physical, mental, or emotional incapacity, resulting from injury, sickness, or disease, as determined by the Executive’s
physician (or his guardian).

 

(c)                
Termination by Company for Cause.          The Company may terminate the Executive’s employment for Cause. For purposes
of this Agreement, “Cause” means the Executive (i) is convicted of a felony which is related to the Executive’s
employment or the business of the Company; (ii) in carrying out his duties hereunder, the Executive has been found in a civil
action to have committed gross negligence or intentional misconduct resulting, in either case, in material harm to the Company;
(iii) subject to a preliminary or permanent injunction issued by a court of competent jurisdiction enjoining the Executive from
violating any federal securities law or any rule or regulation thereunder promulgated by the Securities and Exchange Commission
(the “SEC”); (iv) the Executive becomes subject to a cease and desist order or other order issued by the SEC
after an opportunity for a hearing; or (v) the Executive has been found in a civil action to have materially breached any provision
of Section 8 and/or Section 9 and to have thereby caused material harm to the Company. The term “found
in a civil action” shall not apply until all appeals permissible under the applicable rules of procedure or statutes
have been determined and no further appeals are permissible. to the extent curable.

 

(d)                
Termination by the Company Without Cause.          A termination of the Executive’s employment by the Company for
any reason, except death, disability or Cause, will be deemed to be a termination “Without Cause.”

 

(e)                
Termination by the Executive for Good Reason.          The Executive may terminate his employment for “Good Reason.”
For purposes of this Agreement, “Good Reason” means (i) without the Executive’s written consent, a material
reduction of his duties, positions or responsibilities; (ii) without the Executive’s written consent, a reduction by the
Company in Base Salary as in effect immediately prior to such reduction; (iii) the occurrence of a “Change in Control”
(as defined in Section 6); or (iii) the Company’s material breach of this Agreement; provided that within ninety
(90) days of the Company’s act or omission giving rise to a resignation for Good Reason, the Executive notifies the Company
in writing of the act or omission, the Company fails to correct the act or omission (to the extent curable) within thirty (30)
days after receiving the Executive’s written notice and the Executive actually terminates his employment within sixty (60)
days after the date the Company receives the Executive’s notice.

 

(f)                 
 Termination by the Executive Without Good Reason.          A resignation of the Executive’s employment for any reason
other than Good Reason will be deemed to be a resignation “Without Good Reason.” The Executive may terminate
his employment at any time Without Good Reason, upon thirty (30) days prior written notice to the Company, provided however, the
Company may accelerate the date of such termination to any date following the receipt of such written notice.

 

(g)                
Termination Date.          The “Termination Date” means (i) if the Executive’s employment is
terminated by his death under Section 4(a), the date of his death; (ii) if the Executive’s employment is terminated
on account of his Disability under Section 4(b), the date on which the Company provides the Executive a written termination
notice; (iii) if the Company terminates the Executive’s employment for Cause under Section 4(c), the date on which
the Company provides the Executive a written termination notice; (iv) if the Company terminates the Executive’s employment
Without Cause under Section 4(d), the date on which the Company provides the Executive a written termination notice; (v)
if the Executive resigns his employment for Good Reason under Section 4(e), the date on which the Executive provides the
Company a written termination notice; or (vii) if the Executive resigns his employment Without Good Reason under Section 4(f),
thirty (30) days after the date on which the Executive provides the Company a written termination notice.

 

     

     

    

 2.        Compensation Upon Termination.

 

(a)           Termination by the Company for Cause, upon the Executive’s Death or by the Executive Without Good Reason.     If
the Executive’s employment with the Company is terminated pursuant to Sections 4(a), (c) or (f), the Company
shall pay or provide to the Executive (or to his authorized representative or estate) (i) any earned but unpaid Base Salary as
of the Termination Date; (ii) unpaid expense reimbursements as of the Termination Date; (iii) any earned but unpaid Bonus as of
the Termination Date; and (iv) any vested benefits the Executive may have under any employee benefit plan of the Company (the
“Accrued Obligations”), on or before the time required by law but in no event more than thirty (30) days after
the Termination Date.

 

(b)           Termination for Disability. If the Executive’s Employment is terminated by reason of Disability pursuant to
Section 4(b) then the Executive shall be entitled to the following:

 

(i)          The Company shall pay the Executive the Accrued Obligations earned through the Termination Date, on or before thirty (30) days
after the Termination Date.

 

(ii)         The Options and any subsequent equity award made to the Executive during the Term, shall immediately vest in full and shall be
exercised by the Executive or his legal representatives in accordance with the terms of the applicable employees plan or award
document.

 

(iii)        Subject to the Executive’s timely election of continuation coverage under the Consolidated Omnibus Budget Reconciliation
Act of 1985, as amended (“COBRA”), the Company shall reimburse the Executive the monthly premium payable to
continue his and his eligible dependents’ participation in the Company’s group health plan (to the extent permitted
under applicable law and the terms of such plan) which covers the Executive (and the Executive’s eligible dependents) for
a period of one year from the Termination Date, provided, however, that the Executive remains eligible for COBRA coverage
during such one-year period.

 

(c)           Termination by the Company Without Cause or by the Executive With Good Reason.    If the Executive’s employment
is terminated by the Company Without Cause or the Executive terminates his employment for Good Reason, then the Executive shall
be entitled to the following:

 

(i)          The Company shall pay the Executive the Accrued Obligations earned through the Termination Date, on or before thirty (30) days
after the Termination Date. (

 

(ii)         The Company shall pay the Executive his Base Salary (less applicable withholding taxes) for the balance of the Term, in accordance
with the Company’s normal payroll practices in effect on the Termination Date.

 

(iii)        One hundred percent (100%) of the greater of the Executive’s Bonus for the year of termination or the Bonus actually earned
for the year prior to the year of termination, if any; which amount will be paid within sixty (60) days of the later of the Termination
Date or the calculation of such Bonus.

 

(iv)        The Options and any subsequent equity award made to the Executive during the Term, shall immediately vest in full and shall be
exercised by the Executive or his legal representatives in accordance with the terms of the applicable employees plan or award
document.

 

(v)         Subject to the Executive’s timely election of continuation coverage under the Consolidated Omnibus Budget Reconciliation
Act of 1985, as amended (“COBRA”), the Company shall reimburse the Executive the monthly premium payable to
continue his and his eligible dependents’ participation in the Company’s group health plan (to the extent permitted
under applicable law and the terms of such plan) which covers the Executive (and the Executive’s eligible dependents) for
the period that the Executive is eligible and remains eligible for COBRA coverage, provided, however, that in the event
that the Executive obtains other employment that offers group health benefits, such continuation of coverage by the Company shall
immediately cease.

 

		3.	Change
                                         in Control.

 

(a)           For the purposes of this Agreement, a "Change of Control" shall be deemed to have taken place if (i) any person
who is not an executive officer or director of the Company as of the Effective Date, either individually or as a "group"
as defined in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, becomes the owner or beneficial owner of Company
securities, after the date of this Agreement, having twenty-five percent (25%) or more of the combined voting power of the then
outstanding securities of the Company that may be cast for the election of directors of the Company (other than as a result of
an issuance of securities initiated by the Company, or open market purchases approved by the Board, as long as the majority of
the Board approving the purchases is the majority at the time the purchases are made); or (ii) the persons who were directors
of the Company before such transactions shall cease to constitute a majority of the Board of the Company, or any successor to
the Company, as the direct or indirect result of or in connection with, any cash tender or exchange offer, merger or other business
combination, sale of assets or contested election, or any combination of the foregoing transaction.

 

     

     

    

 

(b)          The Company and the Executive hereby agree that, if the Executive is affiliated with the Company on the date on which a Change
of Control occurs (the "Change of Control Date"), the Company will continue to retain the Executive and the Executive
will remain affiliated with the Company for the period commencing on the Change of Control Date and ending on the third (3rd)
anniversary of the Change in Control Date, to exercise such authority and perform such executive duties as are commensurate with
the authority being exercised and duties being performed by the Executive immediately prior to the Change of Control Date. If
after the Change of Control Executive is requested, and, in his sole and absolute discretion, consents to change his principal
business location, the Company will reimburse the Executive for his reasonable relocation expenses, including, without limitation,
moving expenses, temporary living and travel expenses for a reasonable time while arranging to move his residence to the changed
location, closing costs, if any, associated with the sale of his existing residence and the purchase of a replacement residence
at the changed location, plus an additional amount representing a gross-up of any state or federal taxes payable by the Executive
as a result of any such reimbursement. If the Executive shall not consent to change his business location, the Executive may continue
to provide the services required of him hereunder from his then residence and/or business address, and the Company shall continue
to maintain an office for the Executive at that location commensurate with the Company's office prior to the Change of Control
Date.

 

(c)          During the remaining Term of this Agreement commencing upon the Change of Control Date, the Company will (i) continue to pay Executive
a salary at not less than the level applicable to Executive on the Change of Control Date; (ii) pay Executive Bonuses in amounts
not less in amount than those paid during the twelve (12) month period preceding the Change of Control Date; and (iii) continue
employee benefit programs as to Executive at levels in effect on the Change of Control Date (but subject to such reductions as
may be required to maintain such plans in compliance with applicable federal law regulating employee benefit programs).

 

(d)          If during the remaining Term of this Agreement after the Change of Control Date (i) Executive's employment is terminated by the
Company; or (ii) there shall have occurred a material reduction in Executive's compensation or employment related benefits, or
a material change in the Executive's status, working conditions, management responsibilities or titles, and Executive voluntarily
terminates his relationship with the Company within sixty (60) days of an such occurrence, or the last in a series of occurrences,
then Executive shall be entitled to receive, in addition to the compensation provided for in Section 5(b), and subject
to the provisions of subsections (e) and (f) below, a lump sum payment equal to two hundred ninety-nine percent
(299%) of Executive's “base period income” as determined under (e) below, plus an additional amount representing
a gross-up of any state or federal taxes payable by Executive as a result of any such payment. Such amount will be paid to Executive
within thirty (30) days after his termination of his affiliation with the Company.

 

(e)          The Executive's “base period income” shall be his Base Salary and Bonuses paid or payable to him during or
with respect to the twelve (12) month period preceding the date of his termination of affiliation. If Executive has not been affiliated
for twelve (12) months at the time of his termination of affiliation, his “base period income” shall be his
annualized Base Salary at the rate then in effect and any Performance Bonus paid to Executive prior to the date of his termination
of affiliation or payable to Executive with respect to his period of affiliation.

 

(f)           In the event of a proposed Change in Control, the Company will allow Executive to participate in all meetings and negotiations
related thereto.

 

     

     

    

 

4.           Section 409A Compliance.

 

(a)        All
in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or
incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as
administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year
following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable
expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible
for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or
exchange for another benefit.

 

(b)        To the extent that any of the payments or benefits provided for in Section 5(b) are deemed to constitute non-qualified
deferred compensation benefits subject to Section 409A of the United States Internal Revenue Code (the “Code”),
the following interpretations apply to Section 5: Any termination of the Executive’s employment triggering payment
of benefits under Section 5(b) must constitute a “separation from service” under Section 409A(a)(2)(A)(i)
of the Code and Treas. Reg. §1.409A-1(h) before distribution of such benefits can commence. To the extent that the termination
of the Executive’s employment does not constitute a separation of service under Section 409A(a)(2)(A)(i) of the Code and
Treas. Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated to be provided by the Executive
to the Company or any of its parents, subsidiaries or affiliates at the time the Executive’s employment terminates), any
benefits payable under Section 5 that constitute deferred compensation under Section 409A of the Code shall be delayed
until after the date of a subsequent event constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code and
Treas. Reg. §1.409A-1(h). For purposes of clarification, this Section 7(b) shall not cause any forfeiture of benefits
on the Executive’s part, but shall only act as a delay until such time as a “separation from service”
occurs. Further, if the Executive is a “specified employee” (as that term is used in Section 409A of the Code
and regulations and other guidance issued thereunder) on the date his separation from service becomes effective, any benefits
payable under Section 5 that constitute non-qualified deferred compensation under Section 409A of the Code shall be delayed
until the earlier of (i) the business day following the six-month anniversary of the date his separation from service becomes
effective; and (ii) the date of the Executive’s death, but only to the extent necessary to avoid such penalties under Section
409A of the Code. On the earlier of (i) the business day following the six-month anniversary of the date his separation from service
becomes effective; and (ii) the Executive’s death, the Company shall pay the Executive in a lump sum the aggregate value
of the non-qualified deferred compensation that the Company otherwise would have paid the Executive prior to that date under Section
5(b) of this Agreement. It is intended that each installment of the payments and benefits provided under Section 5(b)
of this Agreement shall be treated as a separate “payment” for purposes of Section 409A of the Code. Neither
the Company nor the Executive shall have the right to accelerate or defer the delivery of any such payments or benefits except
to the extent specifically permitted or required by Section 409A of the Code.

 

5.            Confidential Information.

 

(a)         As used in this Agreement, “Confidential Information” means information belonging to the Company which is of
value to the Company in the course of conducting its business and the disclosure of which could result in a competitive or other
disadvantage to the Company. Confidential Information includes, without limitation, financial information, reports, and forecasts;
inventions, improvements and other intellectual property; trade secrets; know-how; designs, processes or formulae; software; market
or sales information or plans; customer lists; business plans, prospects and opportunities (such as possible acquisitions or dispositions
of businesses or facilities) which have been discussed or considered by the management of the Company. Confidential Information
includes information developed by the Executive in the course of the Executive’s employment by the Company, as well as other
information to which the Executive may have access in connection with his employment. Confidential Information also includes the
confidential information of others with which the Company has a business relationship. Notwithstanding the foregoing, Confidential
Information does not include (i) information which now or in the future comes into the public domain, unless due to breach of
the Executive’s duties under this Section 8(a); (ii) information which is disclosed to Executive by others who are
not, to Executive’s actual knowledge, under obligation of non-disclosure to the Company; (iii) information which is independently
developed by the Executive without breach of the Executive’s duties under this Section 8(a); or (iv) information
which is disclosed by the Company to others without obligation of confidentiality.

 

     

     

    

 

(b)         At all times, both during the Executive’s employment with the Company and after its termination, the Executive will keep
in confidence and trust all Confidential Information, and will not use or disclose for his own benefit or the benefit of any other
Person any such Confidential Information without the written consent of the Company, except as may be necessary in the ordinary
course of performing the Executive’s duties to the Company.

 

6.            Documents, Records, Etc.            All documents, records, data, apparatus, equipment and other physical property, whether
or not pertaining to Confidential Information, which are furnished to the Executive by the Company or are produced by the Executive
in connection with the Executive’s employment will be and remain the sole property of the Company. The Executive will return
to the Company all such materials and property as and when requested by the Company. In any event, the Executive will return all
such materials and property immediately upon termination of the Executive’s employment for any reason. The Executive will
not retain any such material or property or any copies thereof after the termination of his employment.

 

7.            Non-Competition.            From the Effective Date through the second (2nd) anniversary of the Termination Date,
regardless of the reason for such termination or expiration (the “Restricted Period”) the Executive will not,
directly or indirectly, whether as owner, partner, shareholder, consultant, agent, employee, co-venturer or otherwise, engage,
prepare to engage, participate, assist or invest in any Competing Business anywhere in the United States or any other geographic
area in which the Company is actively distributing its products or providing its services as of the Termination Date. Notwithstanding
the foregoing, (i) the Executive may own up to two percent (2%) of the outstanding stock of a publicly held corporation which
constitutes or is affiliated with a Competing Business; and (ii) the Executive may be employed by a large organization which
is engaged in a Competing Business as its non-primary business, so long as Executive is not involved with or assisting such Competing
Business, and so long as Executive does not breach his obligations regarding Confidential Information.

 

11.          No
Solicitation.            During the Restricted Period, the Executive shall not, directly or indirectly, take any of the following
actions, and, to the extent the Executive owns, manages, operates, controls, is employed by or participates in the ownership,
management, operation or control of, or is connected in any manner with, any business, the Executive shall use his best efforts
to ensure that such business does not take any of the following actions:

 

(a)           persuade or attempt to persuade any Customer, Prospective Customer or Supplier to cease doing business with the Company, or to
reduce the amount of business it does with the Company;

 

(b)           solicit or service for himself or for any Person the business of a Customer, Prospective Customer or Supplier in order to provide
goods or services that are competitive with the goods and services provided by the Company;

 

(c)           persuade or attempt to persuade any Service Provider to cease providing services to the Company; or

 

(d)           solicit for hire
or hire for himself or for any third party any Service Provider.

 

The
following definitions are applicable to Sections 8, 9, 10, and 11:

 

(i)          “Competing Business” means the offering in-office ancillary opportunities and third-party billing to physicians
and clinics and any other business in which the services which the Company is engaged in as of the Termination Date.

 

(ii)         “Customer” means any Person that purchased goods or services from the Company at any time within two (2) years
prior to the date of the solicitation prohibited by Sections 11(a) or (b).

 

(iii)           “Prospective Customer” means any Person with whom the Company met or to whom the Company presented for the
purpose of soliciting the Person to become a Customer of the Company within six (6) months prior to the date of the solicitation
prohibited by Sections 11(a) or (b).

 

     

     

    

 

(iv)           “Service Provider” means any Person who is an employee or independent contractor of the Company or the Company
or who was within twelve (12) months preceding the solicitation prohibited by Sections 11(a) or (b) an employee
or independent contractor of the Company or the Company.

 

(v)            “Supplier” means any Person that sold goods or services to the Company at any time within twelve (12) months
prior to the date of the solicitation prohibited by Sections 11(a) or (b).

 

(vi)       “Person”
means an individual, a sole proprietorship, a corporation, a limited liability company, a partnership, an association, a trust,
or other business entity, whether or not incorporated.

  

12.          Intellectual
Property.

 

(a)           All creations, inventions, ideas, designs, copyrightable materials, trademarks, and other technology and rights (and any related
improvements or modifications), whether or not subject to patent or copyright protection (collectively, “Creations”),
relating to any activities of the Company which are conceived by the Executive or developed by the Executive in the course of
his employment with the Company, whether prior to or during the Term, whether conceived alone or with others and whether or not
conceived or developed during regular business hours, shall be the sole property of the Company and, to the maximum extent permitted
by applicable law, shall be deemed “works made for hire” as that term is used in the United States Copyright
Act.

 

(b)           To the extent, if any, that the Executive retains any right, title or interest with respect to any Creations delivered to the
Company or related to his employment with the Company, the Executive hereby grants to the Company an irrevocable, paid-up, transferable,
sub-licensable, worldwide right and license: (i) to modify all or any portion of such Creations, including, without limitation,
the making of additions to or deletions from such Creations, regardless of the medium (now or hereafter known) into which such
Creations may be modified and regardless of the effect of such modifications on the integrity of such Creations; and (ii) to identify
the Executive, or not to identify his, as one or more authors of or contributors to such Creations or any portion thereof, whether
or not such Creations or any portion thereof have been modified. The Executive further waives any “moral” rights,
or other rights with respect to attribution of authorship or integrity of such Creations that he may have under any applicable
law, whether under copyright, trademark, unfair competition, defamation, and right of privacy, contract, tort or other legal theory.

 

(c)           The Executive will promptly inform the Company of any Creations. The Executive will also allow the Company to inspect any Creations
he conceives or develops within one (1) year after the termination of his employment for any reason to determine if they are based
on Confidential Information. The Executive shall (whether during his employment or after the termination of his employment) execute
such written instruments and do other such acts as may be necessary in the opinion of the Company or its counsel to secure the
Company’s rights in the Creations, including obtaining a patent, registering a copyright, or otherwise (and the Executive
hereby irrevocably appoints the Company and any of its officers as his attorney in fact to undertake such acts in his name). The
Executive’s obligation to execute written instruments and otherwise assist the Company in securing its rights in the Creations
will continue after the termination of his employment for any reason. The Company shall reimburse the Executive for any out-of-pocket
expenses (but not attorneys’ fees) he incurs in connection with his compliance with this Section 12(c).

 

13.           Acknowledgement.       The Executive understands that the restrictions set forth in Sections 8, 9, 10, and 11
of this Agreement are intended to protect the Company’s interest in its Confidential Information, goodwill and established
employee and customer relationships, and agrees that such restrictions are reasonable and appropriate for this purpose.

 

     

     

    

 

14.         Indemnification.            During the Term and thereafter, the Company shall indemnify and hold the Executive and the Executive’s
heirs and representatives harmless, to the maximum extent permitted by law, against any and all damages, costs, liabilities, losses
and expenses (including reasonable attorneys’ fees) as a result of any claim or proceeding (whether civil, criminal, administrative
or investigative), or any threatened claim or proceeding (whether civil, criminal, administrative or investigative), against the
Executive that arises out of or relates to the Executive’s service as an officer, director or employee, as the case may
be, of the Company, or the Executive’s service in any such capacity or similar capacity with any affiliate of the Company
or other entity at the Company’s request, both prior to and after the Effective Date, and to promptly advance to the Executive
or the Executive’s heirs or representatives such expenses, including litigation costs and attorneys’ fees, upon written
request with appropriate documentation of such expense upon receipt of an undertaking by the Executive or on the Executive’s
behalf to repay such amount if it shall ultimately be determined that the Executive is not entitled to be indemnified by the Company.
During the Term and thereafter, the Company also shall provide the Executive with coverage under its current directors’
and officers’ liability policy to the same extent that it provides such coverage to its other executive officers. If the
Executive has any knowledge of any actual or threatened action, suit or proceeding, whether civil, criminal, administrative or
investigative, as to which the Executive may request indemnity under this provision, the Executive will give the Company prompt
written notice thereof; provided that the failure to give such notice shall not affect the Executive’s right to indemnification.
The Company shall be entitled to assume the defense of any such proceeding and the Executive will use reasonable efforts to cooperate
with such defense. To the extent that the Executive in good faith determines that there is an actual or potential conflict of
interest between the Company and the Executive in connection with the defense of a proceeding, the Executive shall so notify the
Company and shall be entitled to separate representation at the Company’s expense by counsel selected by the Executive (provided
that the Company may reasonably object to the selection of counsel within ten (10) business days after notification thereof) which
counsel shall cooperate, and coordinate the defense, with the Company’s counsel and minimize the expense of such separate
representation to the extent consistent with the Executive’s separate defense.

 

15.         Survival.            The provisions of Sections 8, 9, 10, 11, 12, 14, 15, 16 and 22 of this Agreement shall
survive its expiration or termination.

 

 16.         Disputes.

 

(a)         The parties agree to resolve any dispute arising under or relating to the interpretation or enforcement of this Agreement, the
Executive’s employment or the termination of the Executive’s employment before the Florida state courts of Miami-Dade
County, Florida or the United States District Court for the Southern District of Florida, and hereby consent to the exclusive
jurisdiction of such courts. Accordingly, with respect to any such court action, the Executive and the Company each (i) submits
to the personal jurisdiction of these courts; (ii) consents to service of process under the notice provisions set forth in
Section 21 of this Agreement; (iii) waives any other requirement (whether imposed by statute, rule of court, or otherwise)
with respect to personal jurisdiction or service of process; and (iv) waives any objection to jurisdiction based on improper venue
or improper jurisdiction.

 

(b)         Notwithstanding anything else provided in this Agreement, the Executive agrees that it would be difficult to measure any damages
caused to the Company which might result from any breach by the Executive of Sections 8, 9, 10, 11 and 12 of this
Agreement. Accordingly, if the Executive breaches or proposes to breach, any term of Sections 8, 9, 10, 11 and 12 of
this Agreement, the Company shall be entitled, in addition to all other remedies that it may have, to a temporary and preliminary
injunction or other appropriate equitable relief to restrain any such breach without showing or providing any actual damage to
the Company from any court having competent jurisdiction over the Executive.

 

(c)         BOTH THE COMPANY AND THE EXECUTIVE HEREBY WAIVE ANY RIGHT TO A TRIAL BY JURY TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE FEDERAL
OR STATE LAW.

 

(d)         The prevailing party shall be entitled to reasonable attorneys’ fees and costs from the non-prevailing party in connection
with any action filed under this Section 16.

 

17.         Integration.            This Agreement constitutes the entire agreement between the parties with respect to the subject
matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including without limitation,
the Original Employment Agreement.

 

18.         Successors.            This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal
representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s
death after his termination of employment but prior to the completion by the Company of all payments due him under this Agreement,
the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his
death (or to his estate, if the Executive fails to make such designation). The Company shall require any successor to the Company
to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required
to perform it if no such succession had taken place.

 

     

     

    

 

19.            
Enforceability.        If any portion or provision of this Agreement (including, without limitation, any portion or
provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction,
then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement
shall be valid and enforceable to the fullest extent permitted by law.

 

20.               
Waiver.         No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving
party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party
of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver
of any subsequent breach.

 

21.               
Notices.         Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient
if in writing and delivered in person or sent by a nationally recognized overnight courier service or by certified mail, postage
prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or,
in the case of the Company, at its main offices, attention of the Chief Financial Officer. Notices shall be effective on receipt,
if delivered by hand, the next business day, if sent by overnight courier service or on the third (3rd) business day
after mailing, if sent by mail.

 

22.               
Amendment.          This Agreement may be amended or modified only by a written instrument signed by the Executive and
by a duly authorized representative of the Company.

 

23.               
Governing Law.       This is a Florida contract and shall be construed under and be governed in all respects by the
laws of Florida for contracts to be performed in that state and without giving effect to the conflict of laws principles of Florida
or any other state.

 

24.               
“Company” Defined.            As used in this Agreement, the term “Company” shall mean the
Company, its parent, subsidiaries and divisions.

 

25.               
Counterparts.            This Agreement may be executed in any number of counterparts, including by facsimile, .PDF or other
electronic transmission (which shall be deemed to be an original), each of which when so executed and delivered shall be taken
to be an original; but such counterparts shall together constitute one and the same document.

 

IN
WITNESS WHEREOF, the parties have executed this Agreement effective as of the Effective Date.

 

	 	THE COMPANY:
	 	 
	 	HEALTH-RIGHT DISCOVERIES, INC.
	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:
	 	 
	 	THE EXECUTIVE:
	 	 
	 	 
	 	David HopkinsEX-10.1

 Exhibit 10.1 

AGCO/SPECCO INTELLECTUAL PROPERTY CROSS LICENSE AGREEMENT 

by and among 
 CORTEVA,
INC., 
 AGCO LICENSORS, 

AGCO LICENSEES, 

DOWDUPONT INC., 
 SPECCO
LICENSORS 
 and 

SPECCO LICENSEES 
 Dated as
of June 1, 2019 

 AGCO/SPECCO INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT 

This AGCO/SPECCO INTELLECTUAL PROPERTY CROSS-LICENSE AGREEMENT (this “Agreement”), dated as of June 1, 2019 (the
“Effective Date”), is entered into by and among Corteva, Inc., a Delaware corporation (“AgCo”), the AgCo Licensors and the AgCo Licensees, on the one hand, and DowDuPont Inc., a Delaware corporation
(“SpecCo”), the SpecCo Licensors and the SpecCo Licensees, on the other hand (each of AgCo and SpecCo, a “Party” and together, the “Parties”). 

WHEREAS, AgCo and SpecCo are parties to that certain Separation and Distribution Agreement, dated April 1, 2019 (the
“Separation Agreement”); 
 WHEREAS, as of and following the Effective Time (as defined in the Separation
Agreement), each Party and its Affiliates have rights to certain Patents, Know-How, Copyrights and Software (each, as defined in the Separation Agreement); and 

WHEREAS, in connection with the Separation Agreement, the SpecCo Licensors wish to grant to the AgCo Licensees, and the AgCo Licensors
wish to grant to the SpecCo Licensees, a license and other rights to certain of such Patents, Know-How, Copyrights and Software, in each case as and to the extent set forth herein. 

NOW, THEREFORE, in consideration of the foregoing and the mutual agreements, provisions and covenants contained in this Agreement, the
Parties hereby agree as follows: 
 ARTICLE I 

DEFINITIONS AND INTERPRETATION 

Section 1.1    General. As used in this Agreement, the following terms shall have the meanings set forth in
this Section 1.1. Capitalized terms that are not defined in this Agreement shall have the meanings set forth in the Separation Agreement. 

(1)    “Action” means any demand, action, claim, cause of action, suit, countersuit, arbitration,
inquiry, case, litigation, subpoena, proceeding or investigation (whether civil, criminal or administrative) by or before any court or grand jury, any Governmental Entity or any arbitration or mediation tribunal or authority. 

(2)    “AgCo Field” means the field of the Agriculture Business and natural evolutions thereof.

 (3)    “AgCo Licensed Copyrights” means any and all Copyrights to the extent Controlled by AgCo or
any of its Affiliates, and Used in the Specialty Products Business, as of the Effective Date, including the Copyrights set forth on Schedule B. Notwithstanding the foregoing, AgCo Licensed Copyrights expressly exclude any and all (i) Know-How, (ii) IT Assets and (iii) Excluded IP. 

  
 2 

 (4)    “AgCo Licensed Engineering Standards” means
Engineering Standards (including as set forth on Schedule E(i)), each, to the extent both (i) owned by AgCo or any of its Affiliates, or with respect to which AgCo or any of its Affiliates has the right to grant the license or other
rights granted to SpecCo hereunder without payment obligations to any Third Party, as of the Effective Date and (ii) that is actually used by SpecCo or its Affiliates in the conduct of the Specialty Products Business as of the Effective Date.
Notwithstanding the foregoing, the AgCo Licensed Engineering Standards shall expressly exclude (i) Regulatory Data, (ii) Governmental Approvals, (iii) CRISPR Technology, (iv) TMODS IP, (v) Trademarks, and (vi) the
Intellectual Property set forth on Schedule A. 
 (5)    “AgCo Licensed IP” means the AgCo
Licensed Patents, AgCo Licensed Know-How, and AgCo Licensed Copyrights. 

(6)    “AgCo Licensed Know-How” means any and all Know-How to the extent Controlled by AgCo or any of its Affiliates, and Used in the Specialty Products Business, as of the Effective Date, including the Know-How set forth on
Schedule C. Notwithstanding the foregoing, AgCo Licensed Know-How expressly excludes any and all (i) IT Assets and (ii) Excluded IP. 

(7)    “AgCo Licensed Patents” means any and all (i) Patents set forth on Schedule D to the
extent Controlled by AgCo or any of its Affiliates as of the Effective Date, (ii) Patents to the extent such Patents Cover any AgCo Licensed Know-How and are Controlled by AgCo or any of its Affiliates
following the Effective Date and (iii) to the extent Controlled by AgCo or any of its Affiliates as of or following the Effective Date, continuations, divisionals, renewals,
continuations-in-part, patents of addition, restorations, extensions, supplementary protection certificates, reissues and
re-examinations of, and all other Patents that claim priority to, any Patents described in either of the foregoing subsections (i) or (ii), and foreign equivalents thereof, in each case to the extent the
claims are supported by any Patents described in either of the foregoing subsections (i) or (ii) (but in all cases expressly excluding any and all Excluded IP). 

(8)    “AgCo Licensed SHE Standards” means the DuPont Safety, Health, and Environmental Standards
(including as set forth on Schedule E(ii)), each, to the extent both (i) owned by AgCo or any of its Affiliates, or with respect to which AgCo or any of its Affiliates has the right to grant the license or other rights granted to SpecCo
hereunder without payment obligations to any Third Party, as of the Effective Date and (ii) that is actually used by SpecCo or its Affiliates in the conduct of the Specialty Products Business as of the Effective
Date.    Notwithstanding the foregoing, the AgCo Licensed SHE Standards shall expressly exclude (i) Regulatory Data, (ii) Governmental Approvals, (iii) CRISPR Technology, (iv) TMODS IP, (v) Trademarks,
and (vi) the Intellectual Property set forth on Schedule A. 
 (9)    “AgCo Licensed
Standards” means the AgCo Licensed SHE Standards and the AgCo Licensed Engineering Standards. 

(10)    “AgCo Licensees” means (a) Pioneer Hi-Bred
International, Inc., with respect to the licenses granted hereunder by PM Taiwan, Inc., and (b) E.I. du Pont de Nemours and Company, with respect to the licenses granted hereunder by DuPont US Holding, LLC, DuPont Industrial Biosciences USA,
LLC, Specialty Products N&H, Inc., DuPont Electronics, Inc., DuPont Safety & Construction, Inc., and DuPont Polymers, Inc. 

  
 3 

 (11)    “AgCo Licensors” means Pioneer Hi-Bred International, Inc. and E.I. du Pont de Nemours and Company. 

(12)    “Authorized User” means a Party and its Affiliates, including, for clarity, any Person that
becomes an Affiliate of such Party after the Effective Date (but, subject to Section 10.2, only for so long as such Person remains an Affiliate of such Party) and its and their Personnel. 

(13)    “Business Software” means with respect to a Licensor, all Software to the extent Controlled by
such Licensor or any of its Affiliates as of the Effective Date, which Software is reasonably required as of the Effective Date for the conduct of (i) the Agriculture Business if the Licensee is AgCo, including as listed on section (i) of
Schedule I, or (ii) the Specialty Products Business if the Licensee is SpecCo, including as listed on section (ii) of Schedule I, in each case (in respect of the foregoing (i) and (ii)), only if and to the extent such
Licensee and its Affiliates have not been granted a license or other rights to use such Software under the Separation Agreement or any other Ancillary Agreement. Notwithstanding the foregoing, Business Software expressly excludes any and all
Excluded IP. 
 (14)    “Confidential Information” shall have the meaning provided to it in the
Umbrella Secrecy Agreement. 
 (15)    “Contract” means any agreement, contract, subcontract,
obligation, note, indenture, instrument, option, lease, sublease, promise, arrangement, release, warranty, license, sublicense, insurance policy, purchase order or legally binding commitment or undertaking of any nature (whether written or oral and
whether express or implied). 
 (16)    “Controlled” means, with respect to any Patent, Know-How, Copyright or Software, (a) such Intellectual Property is owned by the applicable Party or any of its Affiliates and (b) such Party or any of its Affiliates has the ability to grant a license or
other rights in, to or under such Patent, Know-How, Copyright or Software (respectively) on the terms and conditions set forth herein (other than pursuant to a license or other rights granted pursuant to this
Agreement) without violating any Contract entered into as of or prior to the Effective Date between such Party or any of its Affiliates, on the one hand, and any Third Party, on the other hand. 

(17)    “Cover” means, with respect to any Patent, in the absence of a license granted under an unexpired
claim that has not been adjudicated to be invalid or unenforceable by a final, binding decision of a court or other Governmental Entity of competent jurisdiction that is unappealable or unappealed within the time permitted for appeal of such Patent
(or if such Patent is a patent application, a claim in such patent application if such patent application were to issue as a patent), the practice of the applicable invention or technology, or performance of the applicable process, would infringe
such claim. For clarity, and by way of example, an issued Patent Covers a product if, in the absence of a license granted under such a claim of such Patent, making, using, selling, offering for sale, importing or exporting such product infringes
such claim. 

  
 4 

 (18)    “CRISPR Technology” means Intellectual
Property, Confidential Information and any other Information relating to CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) in a nucleic acid and CRISPR-associated proteins (“Cas”) (including Cas9 and other RNA-guided nucleases and other proteins associated with or having a function related to CRISPRs), and applications involving the recognition or function of CRISPRs or Cas proteins. 

(19)    “Engineering Models and Databases” means (a) physical property databases, (b) empirical
or mathematical dynamic or steady state models of processes, equipment and/or reactions and databases containing data resulting from such models, (c) computations of equipment or unit operation operating conditions including predictive or
operational behavior and (d) databases with historical operational data. 
 (20)    “Engineering
Standards” means standards, protocols, processes and policies, including engineering guidelines, for designing, constructing, maintaining and operating facilities. 

(21)    “Excluded IP” means (i) DuPont Safety, Health and Environmental Standards (including AgCo
Licensed SHE Standards and SpecCo Licensed SHE Standards), (ii) Engineering Standards (including the AgCo Licensed Engineering Standards and SpecCo Licensed Engineering Standards), (iii) Regulatory Data, (iv) Governmental Approvals,
(v) CRISPR Technology, (vi) the TMODS Systems (as that term is defined in the TMODS License Agreement) (including object code and source code thereof), together with all process operator training simulator data files which contain process
and control information for simulating the operation of plants, and all documentation therefor (“TMODS IP”), (vii) microbial production strain microorganisms that are Covered by Patents, or incorporate or are produced using Know-How, owned by a Party and its Affiliates, (viii) Trademarks and (ix) the Intellectual Property set forth on Schedule A. 

(22)    “Governmental Approvals” means the consents, registrations, approvals, licenses, permits,
notifications or authorizations obtained or to be obtained from, any Governmental Entity. 

(23)    “Governmental Entity” means any nation or government, any state, municipality or other political
subdivision thereof and any entity, body, agency, commission, department, board, bureau or court, whether domestic, foreign, multinational or supranational exercising executive, legislative, judicial, regulatory, self-regulatory or administrative
functions of or pertaining to government and any executive official thereof. 
 (24)    “Holding Party”
has the meaning set forth in Section 2.10(a). 
 (25)    “Indemnifying Party”
has the meaning set forth in Section 6.1(a). 
 (26)    “Indemnitees” has the
meaning set forth in Section 6.1(a). 
 (27)    “Intellectual Property” means
all intellectual property and industrial property rights of any kind or nature, including all U.S. and foreign (i) patents, patent applications, and all related continuations,
continuations-in-part, divisionals, reissues, re-examinations, substitutions, priority rights and extensions thereof
(collectively “Patents”), (ii) trademarks, service marks, 

  
 5 

 
corporate names, trade names, Internet domain names, social media accounts or handles, logos, slogans, trade dress and other similar designations of source or origin, together with the goodwill
symbolized by any of the foregoing (collectively, “Trademarks”), (iii) copyrights and copyrightable subject matter (collectively, “Copyrights”), (iv) rights of privacy and publicity, (v) moral rights and rights
of attribution and integrity, (vi) trade secrets and rights in all other confidential and proprietary information, including know-how, inventions (including, for the avoidance of doubt, notices of
invention and invention disclosures for which a Patent has not been filed as of the Effective Date (e.g., NOIs and ICDs, as such terms are understood and used by the Parties as of the Effective Date)), algorithms, logic, standard operating
conditions and procedures, proprietary processes, formulae, data, databases and other compilations of data, drawings, models and methodologies, including confidential information set forth in laboratory notebooks, laboratory reports, Plant Operating
Documents, and Engineering Models and Databases (except to the extent such information is Covered by any Patents), in each case of the foregoing, to the extent confidential and proprietary (collectively
“Know-How”), (vii) all applications and registrations for the foregoing and (viii) all rights and remedies against past, present, and future infringement, misappropriation, or other
violation of the foregoing, in each case (with respect to the foregoing clauses (i) through (viii)), excluding all IT Assets (except Software). 

(28)    “Know-How Materials” means those written, electronic,
computerized, digital or other similar tangible or intangible media to the extent containing or embodying any SpecCo Licensed Know-How, AgCo Licensed Know-How, SpecCo
Licensed Copyrights, AgCo Licensed Copyrights, Licensed Standards or Business Software. 
 (29)    “Licensed
Copyrights” means (i) with respect to the licenses granted to SpecCo hereunder, the AgCo Licensed Copyrights and the Copyrights licensed under Section 2.3(a) hereof, and (ii) with respect to the licenses
granted to AgCo hereunder, the SpecCo Licensed Copyrights and the Copyrights licensed under Section 2.3(b) hereof. 

(30)    “Licensed Facility” means any facility owned by or operated on behalf of an Authorized User. 

(31)    “Licensed IP” means (i) with respect to the licenses granted to SpecCo or the SpecCo
Licensees, as applicable, hereunder, the AgCo Licensed IP, the AgCo Licensed Standards, and the Business Software Controlled by AgCo or any of its Affiliates, and (ii) with respect to the licenses granted to AgCo or the AgCo Licensees, as
applicable, hereunder, the SpecCo Licensed IP, the SpecCo Licensed Standards, and the Business Software Controlled by SpecCo or any of its Affiliates. 

(32)    “Licensed Know-How” means (i) with respect to the
licenses granted to SpecCo or the SpecCo Licensees, as applicable, hereunder, the AgCo Licensed Know-How and the Know-How licensed under
Section 2.3(a) hereof, and (ii) with respect to the licenses granted to AgCo or the AgCo Licensees, as applicable, hereunder, the SpecCo Licensed Know-How and the Know-How licensed under Section 2.3(b) hereof. 

(33)    “Licensed Patents” means (i) with respect to the licenses granted to SpecCo or the SpecCo
Licensees, as applicable, hereunder, the AgCo Licensed Patents, and (ii) with respect to the licenses granted to AgCo or the AgCo Licensees, as applicable hereunder, the SpecCo Licensed Patents. 

  
 6 

 (34)    “Licensed Standards” means (i) with
respect to the licenses granted to SpecCo or the SpecCo Licensees, as applicable, hereunder, the AgCo Licensed Standards and (ii) with respect to the licenses granted to AgCo or the AgCo Licensees, as applicable hereunder, the SpecCo Licensed
Standards. 
 (35)    “Licensee” means (i) the relevant AgCo Licensee with respect to the SpecCo
Licensed IP and the SpecCo Licensed Standards, and AgCo and its applicable Affiliates with respect to the Business Software Controlled by SpecCo or any of its Affiliates hereunder, and (ii) the relevant SpecCo Licensees with respect to the AgCo
Licensed IP and the AgCo Licensed Standards, and SpecCo and its applicable Affiliates with respect to the Business Software Controlled by AgCo or any of its Affiliates hereunder. 

(36)    “Licensor” means (i) the AgCo Licensors with respect to the AgCo Licensed IP and the AgCo
Licensed Standards, and AgCo with respect to the Business Software Controlled by AgCo or any of its Affiliates, and (ii) the SpecCo Licensors with respect to the SpecCo Licensed IP and the SpecCo Licensed Standards, and SpecCo with respect to
the Business Software Controlled by SpecCo or any of its Affiliates. 
 (37)    “Merger Time” means the
effective time of the mergers of E. I. du Pont de Nemours and Company and the Dow Chemical Company with wholly owned subsidiaries of DowDuPont, Inc. 

(38)    “Notifying Party” has the meaning set forth in Section 2.5(a). 

(39)    “Personnel” means, with respect to a Party or its Affiliates, such Party’s or
Affiliate’s employees, officers, agents, consultants, and contractors, and any other Person over whom such Party or Affiliate exercises control. 

(40)    “Receiving Party” has the meaning set forth in Section 2.5(a). 

(41)    “Regulatory Data” means any and all regulatory data (including studies, data, raw data, efficacy
data, reports, physical samples, reviews (including business risk reviews), opinions, self-GRAS determinations, information or other compliance requirements, including safety, risk and exposure assessments and modeling for product contamination or
impurity issues), in written, electronic, computerized, digital, or other tangible or intangible media, actually submitted to, or maintained to support a submission to (whether submitted or not), a Governmental Entity or a Third Party to seek,
obtain or maintain a Governmental Approval or demonstrate regulatory compliance. 
 (42)    “Requesting
Party” has the meaning set forth in Section 2.10(a). 
 (43)    “Seeds and
Beads IP” means all Intellectual Property expressly identified on Schedules C and D as relating to “seeds and beads”. 

  
 7 

 (44)    “Software” means all computer programs (whether
in source code, object code, or other form), software implementations of algorithms, and related documentation, including flowcharts and other logic and design diagrams, technical, functional and other specifications, and user and training materials
related to any of the foregoing. 
 (45)    “SpecCo Field” means the field of the Specialty Products
Business and natural evolutions thereof. 
 (46)    “SpecCo Licensed Copyrights” means any and
all Copyrights to the extent Controlled by SpecCo or any of its Affiliates, and Used in the Agriculture Business, as of the Effective Date, including the Copyrights set forth on Schedule F. Notwithstanding the foregoing, SpecCo Licensed
Copyrights expressly exclude any and all (i) Know-How, (ii) IT Assets and (iii) Excluded IP. 

(47)    “SpecCo Licensed Engineering Standards” means Engineering Standards (including as set forth on
Schedule E(iii)), each, to the extent both (i) owned by SpecCo or any of its Affiliates, or with respect to which SpecCo or any of its Affiliates has the right to grant the license or other rights granted to AgCo hereunder without
payment obligations to any Third Party, as of the Effective Date and (ii) that is actually used by AgCo or its Affiliates in the conduct of the Agriculture Business as of the Effective Date. Notwithstanding the foregoing, the SpecCo Licensed
Engineering Standards shall expressly exclude (i) Regulatory Data, (ii) Governmental Approvals, (iii) CRISPR Technology, (iv) TMODS IP, (v) Trademarks, and (vi) the Intellectual Property set forth on Schedule A.

 (48)    “SpecCo Licensed IP” means the SpecCo Licensed Patents, SpecCo Licensed Know-How and SpecCo Licensed Copyrights. 
 (49)    “SpecCo Licensed Know-How” means any and all Know-How to the extent Controlled by SpecCo or any of its Affiliates, and Used in the Agriculture Business, as of the Effective Date,
including the Know-How set forth on Schedule G. Notwithstanding the foregoing, SpecCo Licensed Know-How expressly excludes any and all (i) IT Assets and
(ii) Excluded IP. 
 (50)    “SpecCo Licensed Patents” means any and all (i) Patents set
forth on Schedule H to the extent Controlled by SpecCo or any of its Affiliates as of the Effective Date, (ii) Patents to the extent such Patents Cover any SpecCo Licensed Know-How and are
Controlled by SpecCo or any of its Affiliates following the Effective Date and (iii) to the extent Controlled by SpecCo or any of its Affiliates as of or following the Effective Date, continuations, divisionals, renewals, continuations-in-part, patents of addition, restorations, extensions, supplementary protection certificates, reissues and
re-examinations of, and all other Patents that claim priority to, any Patents described in either of the foregoing subsections (i) or (ii), and foreign equivalents thereof, in each case to the extent the
claims are supported by any Patents described in either of the foregoing subsections (i) or (ii) (but in all cases expressly excluding any and all Excluded IP). 

  
 8 

 (51)    “SpecCo Licensed SHE Standards” means the
DuPont Safety, Health, and Environmental Standards (including as set forth on Schedule E(iv)), each, to the extent both (i) owned by SpecCo or any of its Affiliates, or with respect to which SpecCo or any of its Affiliates has the
right to grant the license or other rights granted to AgCo hereunder without payment obligations to any Third Party, as of the Effective Date and (ii) that is actually used by AgCo or its Affiliates in the conduct of the Agriculture Business as
of the Effective Date.    Notwithstanding the foregoing, the SpecCo Licensed SHE Standards shall expressly exclude (i) Regulatory Data, (ii) Governmental Approvals, (iii) CRISPR Technology, (iv) TMODS IP,
(v) Trademarks, and (vi) the Intellectual Property set forth on Schedule A. 
 (52)    “SpecCo
Licensed Standards” means the SpecCo Licensed SHE Standards and the SpecCo Licensed Engineering Standards. 

(53)    “SpecCo Licensees” means (a) PM Taiwan, Inc., with respect to the licenses granted hereunder
by Pioneer Hi-Bred International, Inc., and (b) DuPont US Holding, LLC, DuPont Industrial Biosciences USA, LLC, Specialty Products N&H, Inc., DuPont Electronics, Inc., DuPont Safety &
Construction, Inc., and DuPont Polymers, Inc., with respect to licenses granted hereunder by E.I. du Pont de Nemours and Company. 

(54)    “SpecCo Licensors” means PM Taiwan, Inc., DuPont US Holding, LLC, DuPont Industrial
Biosciences USA, LLC, Specialty Products N&H, Inc., DuPont Electronics, Inc., DuPont Safety & Construction, Inc., and DuPont Polymers, Inc. 

(55)    “Sublicensee” has the meaning set forth in Section 2.6(a). 

(56)    “Term” has the meaning set forth in Section 8.1. 

(57)    “Third Party” means any Person other than AgCo, SpecCo, and their respective Affiliates. 

(58)    “Third Party Infringement” means (a) any Third Party activities that constitute, or would
reasonably be expected to constitute, an infringement, misappropriation or other violation within the field for which Licensee has been granted a license hereunder of any Licensed IP or (b) any Third Party allegations of invalidity or
unenforceability of any Licensed IP. 
 (59)    “Third Party Payments” means any and all obligations on
the part of Licensor or its Affiliates to pay royalties, sublicense fees, milestones or other amounts to Third Parties pursuant to Contracts existing as of the Effective Date (or, in the case of Wrong Pockets Patents, Contracts existing as of the
date of the Wrong Pockets Notice) to which Licensor or any of its Affiliates is a party or is otherwise bound, in each case to the extent that such obligation to pay arises from, or is a result of the grant to or exercise by Licensee or any
Sublicensees of, any license, sublicense or other right to practice granted hereunder. 
 (60)    “TMODS License
Agreement” means that certain DuPont TMODS Dynamic Process Simulation Software Agreement entered into by and between AgCo and SpecCo, dated as of the Effective Date. 

(61)    “Umbrella Secrecy Agreement” means the Umbrella Secrecy Agreement, dated as of the Effective
Date, between SpecCo, AgCo and the other signatories thereto. 

  
 9 

 (62)    “Used” means, with respect to the applicable
Patent, Copyright or Know-How, that, as of the Effective Date, (i) such Intellectual Property is actually used, or (ii) (1) there is a bona fide plan and intention to use such Intellectual Property
with a product that is expected to be commercially launched within eight and one half (8.5) years of the Effective Date or that is set forth on Schedule J, and (2) senior management has agreed to or approved, in writing, a capital
investment or commitment to allocate resources or man-hours to implement such plan and intention, in each case in respect of the foregoing subsections (i) and (ii), as established by contemporaneous
written records created in the ordinary course of business (which records shall be in a form consistent with the form that actual use, or similar plans and approvals, as applicable, were documented by the applicable Party (or its predecessors in
interest) prior to the Merger Time). 
 (63)    “Wrong Pockets Notice” shall have the meaning set forth
in Section 2.5(a). 
 (64)    “Wrong Pockets Patent” shall have the meaning
set forth in Section 2.5(c). 
 Section 1.2    References; Interpretation. For
the purposes of this Agreement, (a) words in the singular shall be held to include the plural and vice versa, and words of one gender shall be held to include the other gender as the context requires; (b) references to the terms Article,
Section, paragraph, clause, Exhibit and Schedule are references to the Articles, Sections, paragraphs, clauses, Exhibits and Schedules to this Agreement unless otherwise specified; (c) the terms “hereof,” “herein,”
“hereby,” “hereto,” and derivative or similar words refer to this entire Agreement, including the Schedules and Exhibits hereto; (d) references to “$” shall mean U.S. dollars; (e) the word
“including” and words of similar import when used in this Agreement shall mean “including without limitation,” unless otherwise specified; (f) the word “or” shall not be exclusive; (g) references to
“written” or “in writing” include in electronic form; (h) the headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement; (i) the
Parties have each participated in the negotiation and drafting of this Agreement and, except as otherwise stated herein, if an ambiguity or question of interpretation should arise, this Agreement shall be construed as if drafted jointly by the
Parties and no presumption or burden of proof shall arise favoring or burdening any Party by virtue of the authorship of any of the provisions in this Agreement; (j) a reference to any Person includes such Person’s successors and permitted
assigns; (k) any reference to “days” means calendar days unless Business Days are expressly specified; (l) when calculating the period of time before which, within which or following which any act is to be done or step taken
pursuant to this Agreement, the date that is the reference date in calculating such period shall be excluded and if the last day of such period is not a Business Day, the period shall end on the next succeeding Business Day; (m) any statute
defined or referred to herein means such statute as from time to time amended, modified or supplemented, unless otherwise specifically indicated; (n) the use of the phrases “the date of this Agreement”, “the date hereof”,
“of even date herewith” and terms of similar import shall be deemed to refer to the date set forth in the preamble to this Agreement; (o) the phrase “ordinary course of business” shall be deemed to be followed by the words
“consistent with past practice” whether or not such words actually follow such phrase; (p) where a word or phrase is defined herein, each of its other grammatical forms shall have a corresponding meaning; and (q) any consent
given by any Party pursuant to this Agreement shall be valid only if contained in a written instrument signed by such Party. Unless the context requires otherwise, references in this Agreement to “SpecCo” shall also be

  
 10 

 
deemed to refer to the applicable member of the SpecCo Group, references to “AgCo” shall also be deemed to refer to the applicable member of the AgCo Group and, in connection therewith,
any references to actions or omissions to be taken, or refrained from being taken, as the case may be, by SpecCo or AgCo shall be deemed to require SpecCo or AgCo, as the case may be, to cause the applicable members of the SpecCo Group or the AgCo
Group, respectively, to take, or refrain from taking, any such action. 
 ARTICLE II 

GRANTS OF RIGHTS 

Section 2.1    Licenses to SpecCo of AgCo Licensed IP. 

(a)    Non-Exclusive License to
Know-How and Copyrights. Subject to the terms and conditions of this Agreement, the AgCo Licensors hereby grant, and AgCo shall cause its Affiliates to grant, to the relevant SpecCo Licensees an
irrevocable, royalty-free, fully paid-up, sublicensable (to the extent permitted in Section 2.6), transferable (subject to Section 10.2), worldwide, non-exclusive license in, to and under the AgCo Licensed Know-How and the AgCo Licensed Copyrights for any and all uses in the SpecCo Field. For clarity, subject to the terms
and conditions of this Agreement, the license in, to and under the applicable AgCo Licensed IP set forth in this Section 2.1(a) shall include the right to practice the same to make (including have made), use, sell, offer
for sale, import, and export any and all products within the SpecCo Field, and use, practice, copy, perform, render, develop, improve, display, redistribute, modify, and make derivative works of such AgCo Licensed IP, within the SpecCo Field. 

(b)    Non-Exclusive License to Patents. Subject to the terms and
conditions of this Agreement, the AgCo Licensors hereby grant to the relevant SpecCo Licensees, an irrevocable, royalty-free, fully paid-up, sublicensable (to the extent permitted in
Section 2.6), transferable (subject to Section 10.2), worldwide, non-exclusive license in, to and under the AgCo Licensed Patents for any and all uses in the
SpecCo Field. For clarity, subject to the terms and conditions of this Agreement, the license in, to and under the AgCo Licensed Patents set forth in this Section 2.1(b) shall include the right to practice the same to make
(including have made), use, sell, offer for sale, import, and export any and all products within the SpecCo Field. 

Section 2.2    Licenses to AgCo of SpecCo Licensed IP. 

(a)    Non-Exclusive License to
Know-How and Copyrights. Subject to the terms and conditions of this Agreement, the SpecCo Licensors hereby grant, and SpecCo shall cause its Affiliates to grant, to the relevant AgCo Licensees an
irrevocable, royalty-free, fully paid-up, sublicensable (to the extent permitted in Section 2.6), transferable (subject to Section 10.2), worldwide, non-exclusive license in, to and under the SpecCo Licensed Know-How and SpecCo Licensed Copyrights for any and all uses in the AgCo Field. For clarity, subject to the terms
and conditions of this Agreement, the license in, to and under the applicable SpecCo Licensed IP set forth in this Section 2.2(a) shall include the right to practice the same to make (including have made), use, sell, offer
for sale, import, and export any and all products within the AgCo Field, and use, practice, copy, perform, render, develop, improve, display, redistribute, modify, and make derivative works of such SpecCo Licensed IP, within the AgCo Field. 

  
 11 

 (b)    Non-Exclusive License
to Patents. Subject to the terms and conditions of this Agreement, the SpecCo Licensors hereby grant to the relevant AgCo Licensees, an irrevocable, royalty-free, fully paid-up, sublicensable (to the
extent permitted in Section 2.6), transferable (subject to Section 10.2), worldwide, non-exclusive license in, to and under the SpecCo Licensed Patents for
any and all uses in the AgCo Field. For clarity, subject to the terms and conditions of this Agreement, the license in, to and under the SpecCo Licensed Patents set forth in this Section 2.2(b) shall include the right to
practice the same to make (including have made), use, sell, offer for sale, import, and export any and all products within the AgCo Field. 

Section 2.3    Licenses to Standards. 

(a)    Subject to the terms and conditions of this Agreement, the applicable AgCo Licensors hereby grant, and AgCo shall
cause its Affiliates to grant, to the relevant SpecCo Licensees, an irrevocable, royalty-free, fully paid-up, sublicensable (to the extent permitted in Section 2.6), transferable
(subject to Section 10.2), non-exclusive license to use the AgCo Licensed Standards at the SpecCo Licensed Facilities solely in connection with the conduct of the Specialty Products
Business by SpecCo or any of its Affiliates. Without limiting the foregoing, the grant in this Section 2.3 includes a right and license to use, reproduce, distribute, display, perform, adapt, modify and create derivative
works of the AgCo Licensed Standards by and among the Authorized Users only for the licensed uses set forth in this Section 2.3. 

(b)    Subject to the terms and conditions of this Agreement, the applicable SpecCo Licensors hereby grant, and SpecCo
shall cause its Affiliates to grant, to the relevant AgCo Licensees, an irrevocable, royalty-free, fully paid-up, sublicensable (to the extent permitted in Section 2.6), transferable
(subject to Section 10.2), non-exclusive license to use the SpecCo Licensed Standards at the AgCo Licensed Facilities solely in connection with the conduct of the Agriculture Business
by AgCo or any of its Affiliates. Without limiting the foregoing, the grant in this Section 2.3 includes a right and license to use, reproduce, distribute, display, perform, adapt, modify and create derivative works of the
SpecCo Licensed Standards by and among the Authorized Users only for the licensed uses set forth in this Section 2.3. 

(c)    Notwithstanding anything to the contrary herein, neither Licensor nor any of its Affiliates shall have any
obligation with respect to training Licensee or any of its Affiliates to implement or use the Licensed Standards. For clarity, the Licensed Standards shall not be subject to any updates by Licensor or its Affiliates (even if Licensor or its
Affiliates update the same for their own use). The Parties acknowledge that from time to time applicable Law may conflict with and supersede aspects of Licensed Standards and Licensor shall have no obligation to Licensee with respect thereto in such
event. For clarity, as between the Parties, SpecCo shall own all Intellectual Property (including, for clarity, Copyrights) in any DuPont Safety, Health and Environmental Standards or Engineering Standards that constitute Intellectual Property
included in the Specialty Products Assets, and AgCo shall own all Intellectual Property (including, for clarity, Copyrights) in any DuPont Safety, Health and Environmental Standards or Engineering Standards that constitute Intellectual Property
included in the Agriculture Assets. 

  
 12 

 Section 2.4    Business Software License. Subject to the
terms and conditions of this Agreement, Licensor (or its Affiliate, as applicable) hereby grants, and shall cause its Affiliates to grant, to Licensee (or its Affiliate, as applicable) an irrevocable, royalty-free, fully paid-up, sublicensable (to the extent permitted in Section 2.6), transferable (subject to Section 10.2), worldwide,
non-exclusive license to its Business Software for use solely in connection with, if such Licensee is AgCo, the Agriculture Business or, if such Licensee is SpecCo, the Specialty Products Business, including
in each case, for clarity, natural evolutions of such Business. 
 Section 2.5    Wrong Pockets. 

(a)    A Party (a “Notifying Party”) shall have the right to provide prompt written notice (a
“Wrong Pockets Notice”) to the other Party (a “Receiving Party”), including in response to an inquiry from the Receiving Party, if, following the Effective Date: 

(i)    a Notifying Party identifies a Patent Controlled by the other Party as of the Effective Date that
is not included in the Licensed Patents licensed to such Notifying Party, and such Notifying Party reasonably believes that such Patent was Used in the Agriculture Business or the Specialty Products Business, as applicable, as of the Effective Date;
or 
 (ii)    a Notifying Party identifies a Use by such Notifying Party of a Licensed Patent
(including, for clarity, any Wrong Pockets Patent) that is not within such Notifying Party’s licensed field of use hereunder for such Licensed Patent, and such Notifying Party reasonably believes that the Use of such Licensed Patent as of the
Effective Date was within the Agriculture Business (if AgCo is the Notifying Party) or the Specialty Products Business (if SpecCo is the Notifying Party). 

(b)    Each Wrong Pockets Notice shall both identify the applicable Patent and describe the Use thereof in the
Agriculture Business (if the Notifying Party is AgCo), or the Specialty Products Business (if the Notifying Party is SpecCo), as of the Effective Date. 

(c)    Unless otherwise agreed in writing by the Parties, if a Notifying Party provides a Wrong Pockets Notice in
accordance with Section 2.5(a), the Notifying Party shall, within sixty (60) days of providing the Wrong Pockets Notice, demonstrate to the Receiving Party by clear and convincing evidence (the “Evidentiary
Requirement”) that the identified Patent was Used in the manner identified in the Wrong Pockets Notice within the Agriculture Business (if the Notifying Party is AgCo) or the Specialty Products Business (if the Notifying Party is SpecCo) as
of the Effective Date (such evidence, the “Demonstration of Use”). The Receiving Party shall notify the Notifying Party in writing within thirty (30) days of receipt of the Demonstration of Use whether it reasonably believes in
good faith that the Demonstration of Use satisfies the Evidentiary Requirement. Solely to the extent (with respect to the Patent and Use identified in the applicable Wrong Pockets Notice) that the Demonstration of Use satisfies the Evidentiary
Requirements (whether determined by the Receiving Party in 

  
 13 

 
accordance with the foregoing, or in accordance with Section 9.1), or if the Receiving Party fails to provide the Notifying Party with a response regarding whether the
Demonstration of Use satisfies the Evidentiary Requirements within the applicable thirty (30) day period in accordance with the foregoing, such Patent shall be licensed to the Notifying Party for such Use (in the case of a Wrong Pockets Notice
described in Section 2.5(a)(i)) (each such Patent, a “Wrong Pockets Patent”), or such Use shall be included in the Notifying Party’s field of use for such Patent (in the case of a Wrong
Pockets Notice described in Section 2.5(a)(ii)), as applicable, in each case, as further described in the following subsections (i) and (ii). 

(i)    Subject to the foregoing in this Section 2.5(c), unless otherwise agreed
in writing by the Parties, with respect to a Wrong Pockets Notice described in Section 2.5(a)(i), each Patent identified in such notice (if the Demonstration of Use therefor satisfies the Evidentiary Requirement or the
Receiving Party fails to provide the Notifying Party with a response in accordance with this Section 2.5(c)) shall be a SpecCo Licensed Patent if AgCo is the Notifying Party or an AgCo Licensed Patent if SpecCo is the
Notifying Party, and for clarity, the license to the Notifying Party therefor shall be non-exclusive and the field for which it is licensed pursuant to this Agreement (which, notwithstanding anything to the
contrary herein, shall be deemed to be the AgCo Field for such Patent if AgCo is the Notifying Party and the SpecCo Field for such Patent if SpecCo is the Notifying Party) shall be limited solely to the Use made by such Notifying Party and its
Affiliates as of the Effective Date (to the extent that the Demonstration of Use therefor satisfies the Evidentiary Requirement) and natural evolutions thereof, subject to the terms and conditions of any licenses and other rights granted by or on
behalf of Licensor or any of its Affiliates to any Third Parties with respect to such Patent prior to the date of the Wrong Pockets Notice. 

(ii)    Subject to the foregoing in this Section 2.5(c), unless otherwise agreed
in writing by the Parties, with respect to a Wrong Pockets Notice described in Section 2.5(a)(ii), each Use for a Licensed Patent identified in the Wrong Pockets Notice (to the extent that Demonstration of Use therefor
satisfies the Evidentiary Requirement or the Receiving Party fails to provide the Notifying Party with a response in accordance with this Section 2.5(c)) and natural evolutions thereof shall be deemed to be in the AgCo
Field for such Licensed Patent if AgCo is the Notifying Party and in the SpecCo Field for such Licensed Patent if SpecCo is the Notifying Party and the license granted to such field shall be nonexclusive; provided that the rights with
respect to such Use retained by the Notifying Party shall be subject to the terms and conditions of any licenses and other rights granted by or on behalf of the Receiving Party or any of its Affiliates to any Third Parties with respect to such
Patent prior to the date of the Wrong Pockets Notice. 
 (d)    Notwithstanding anything to the contrary herein, unless
otherwise agreed upon by the Parties, each Party shall only have two (2) years after the Effective Date to provide a Wrong Pockets Notice pursuant to Section 2.5(a) to the other Party; provided that, in
the case of Section 2.5(a)(i), with respect to Patent applications filed prior to the Effective Date, 

  
 14 

 
such period shall extend until the date that is six (6) months after the publication of such Patent application if the expiration of such six (6) month period occurs after such two
(2) year period expires. 
 (e)    Notwithstanding the foregoing Sections 2.5(a) through (d), unless
and only to the extent that the Receiving Party provides its prior written consent (which the Receiving Party may withhold in its sole discretion), in the event that the Parties expressly discussed prior to the Effective Date that: 

(i)    any Patent would not be included in the Notifying Party’s Licensed Patents in the case of a
Wrong Pockets Notice described in Section 2.5(a)(i), such Patent shall not be included in the Notifying Party’s Licensed Patents (provided that, in determining that such Patent would not be a Licensed
Patent hereunder, the Parties discussed prior to the Effective Date the Use identified in the Wrong Pockets Notice for such Patent); or 

(ii)    any Use would not be included in the Notifying Party’s field of use for a specific Licensed
Patent in the case of a Wrong Pockets Notice described in Section 2.5(a)(ii) (as applicable), such Use shall not be included in the Notifying Party’s licensed field of use for such Patent. 

(f)    Notwithstanding the foregoing Sections 2.5(a) through 2.5(e), those patents set forth on Schedule
K are specifically excluded from and are not subject to a Wrong Pockets Notice. 

Section 2.6    Sublicenses. 

(a)    Licensee may sublicense the license and rights granted to Licensee under Sections 2.1 through 2.4 (as
applicable) to (i) its Affiliates, (ii) in the case of all Licensed IP other than the Seeds and Beads IP, Third Parties in connection with the operation of the business of Licensee or its Affiliates, but not for the independent use of any
such Third Party, including distributors that need to practice the applicable Intellectual Property to provide ordinary course distribution services to Licensee and its Affiliates; provided that, with respect to the Licensed Standards,
sublicensing to such Third Parties shall be solely for such Third Parties to provide services to the Specialty Products Business or Agriculture Business (as applicable) in the ordinary course at any or all Licensed Facilities (but not for the
independent use of such Third Party), (iii) in the case of the Seeds and Beads IP, to Third Parties (1) who are bona fide collaborators or partners of Licensee or any of its Affiliates, or (2) in connection with which sublicense Licensee
or any of its Affiliates is also granting a license or other rights to any other Intellectual Property for seed coating and seed treatment technology owned by or licensed to Licensee or any of its Affiliates, in each case (1) and (2), for use
in connection with the practice of seed coating and seed treatment technology, and (iv) with the prior written consent of Licensor, other Third Parties (each such Affiliate or Third Party, a “Sublicensee”). 

(b)    Each sublicense granted by a Licensee under the license granted to such Licensee in Sections 2.1 through
2.4 shall be granted pursuant to an agreement that (i) is subject to, and consistent with, the terms and conditions of this Agreement and includes 

  
 15 

 
provisions at least as protective of Licensor and its Affiliates as the provisions of this Agreement (except that such sublicense shall not be required to provide rights for Licensor to audit
Sublicensee in accordance with, and subject to, Section 2.11 (1) if the sublicense is granted to an Affiliate or (2) with respect to sublicenses of Licensed Know-How, Licensed
Copyrights or Business Software where the primary purpose of such arrangement with sublicensee is not to grant access to such Licensed Know-How, Licensed Copyrights or Business Software), (ii) to the extent
with respect to Licensed Patents or AgCo Licensed Standards and if Sublicensee is a Third Party, provides that Licensor shall be an intended beneficiary thereunder with the right of direct enforcement against the Sublicensee (including, for clarity,
with respect to the audit rights set forth in Section 2.11 to the extent applicable), and (iii) to the extent with respect to Licensed Patents or AgCo Licensed Standards, is in writing if the Sublicensee is a Third
Party. For clarity, granting a sublicense shall not relieve Licensee of any obligations hereunder and Licensee shall cause each of its Sublicensees to comply, and shall remain responsible for its Sublicensees’ compliance, with the terms hereof
applicable to Licensee. 
 Section 2.7    Third Party Rights. 

(a)    Notwithstanding anything to the contrary herein, the terms and conditions of this Agreement (including the licenses
granted under Sections 2.1 through 2.4) are subject to any and all rights of and obligations owed to any Third Parties with respect to the Licensed IP under any Contracts existing as of the Effective Date (or in the case of any Wrong
Pockets Patents, existing as of or prior to the date of the Wrong Pockets Notice) to which Licensor or any of its Affiliates is a party or is otherwise bound, and to the extent that, as a result of such rights or obligations, any license or other
rights granted hereunder: (i) may not be granted without the consent of or payment of a fee or other consideration; or (ii) will cause Licensor or any of its Affiliates to be in breach of any of its or their obligations to any Third Party,
the applicable licenses and other rights granted hereunder shall only be granted to the extent such consent has been obtained or such fee or other consideration has been paid. The Parties shall use commercially reasonable efforts to obtain any such
consents to the extent required to grant Licensee the rights granted hereunder; provided that, (i) the foregoing shall not require the Parties to duplicate any obligations undertaken under the Separation Agreement and
(ii) notwithstanding anything herein to the contrary, Licensor shall have no obligation to agree to or make any payments or other concessions, except as mutually agreed in writing between the Parties, or participate in any act or omission that
will cause Licensor to be in breach of its or their obligations to any Third Party. Notwithstanding the foregoing, Licensee shall not be deemed in breach of this Section 2.7(a) only if, and for such time, Licensee is not
aware of such rights of or obligations owed to such Third Party. 
 (b)    Notwithstanding anything to the contrary
herein, Third Party Payments, if any, with respect to the Licensed IP shall be Licensee’s sole responsibility. Licensee shall pay the Third Party Payments directly to the applicable Third Party; provided that if such Third Party
does not permit Licensee to pay such Third Party Payments to such Third Party directly (whether pursuant to the applicable Contract or otherwise) after the Parties have used commercially reasonable efforts to permit the Licensee to pay the Third
Party directly, the Parties shall cooperate in good faith to ensure that such Third Party Payments are paid by Licensee to Licensor in a manner that ensures Licensor’s payment thereof is in compliance with the obligations to the applicable
Third Party. Such cooperation shall include Licensee (i)

  
 16 

 
preparing and providing Licensor with reasonably detailed written reports reflecting calculation of the applicable Third Party Payments and any other information required by the applicable Third
Parties and (ii) paying Licensor the applicable Third Party Payments by wire transfer of immediately available funds to the bank account designated by Licensor in writing no less than ten (10) days prior to the due date of such payment
pursuant to the terms of the applicable Contract. If either Party becomes aware of any Third Party Payments, it shall reasonably promptly notify the other Party in writing, and notwithstanding anything to the contrary in this
Section 2.7(b), Licensee shall not be deemed in breach of this Section 2.7(b) if, and for such time, Licensee is not aware of the applicable Third Party Payments; provided that, upon
learning of such Third Party Payments, Licensee shall promptly pay such Third Party Payments to the applicable Third Party directly (or such other Person as reasonably directed by Licensor) to the extent such Third Party Payments are past due. 

(c)    Certain agreements subject to Subsections (a) and (b) hereof are set forth on Schedule L hereto. 

Section 2.8    No Use Outside Field. Each Party shall not, and shall cause its Affiliates to not, as
Licensee, exercise rights under any Licensed IP except to the extent expressly licensed hereunder or expressly agreed upon in advance in writing by Licensor. 

Section 2.9    Reservation of Rights. Each Party reserves its and its Affiliates’ rights in and to all
Intellectual Property that is not expressly licensed or otherwise granted hereunder. Without limiting the foregoing, this Agreement and the licenses and rights granted herein do not, and shall not be construed to, confer any rights upon either
Party, its Affiliates, or its Sublicensees by implication, estoppel, or otherwise as to any of the other Party’s Intellectual Property (including, for clarity, any Excluded IP, except to the extent expressly licensed under
Section 2.3). 
 Section 2.10    Retention and Transfer of Licensed Know-How. 
 (a)    If AgCo or SpecCo (the “Requesting Party”)
reasonably believes that any Know-How Materials are in possession or control of the other Party (such Party, the “Holding Party”) or any of its Affiliates and such Know-How Materials are not in the possession or control of the Requesting Party or any of its Affiliates, and the Requesting Party makes a request in writing during the two (2) year period following the
Effective Date that the Holding Party deliver the Know-How Materials to the Requesting Party, the Holding Party shall review such request and, to the extent in the possession or control of the Holding Party or
any of its Affiliates and, for purposes of Business Software only, is reasonably accessible to the Holding Party for purposes of transfer to the Requesting Party (provided that, subject to the below provisos, such accessibility shall
not take into account whether such Business Software is integrated with other Software), deliver the Know-How Materials to the Requesting Party as promptly as reasonably practicable and in any event within
thirty (30) Business Days of receiving such request from the Requesting Party; provided that, the Holding Party shall notify the Requesting Party within such thirty (30) Business Day period if it reasonably believes that such
request requires a longer period of review to determine if the request concerns SpecCo Licensed Know-How, AgCo Licensed Know-How, SpecCo Licensed Copyrights, AgCo
Licensed Copyrights, AgCo Licensed Standards or Business Software (as applicable) or to locate 

  
 17 

 
the applicable Know-How Materials, and the Holding Party shall take all reasonable steps to review and provide such
Know-How Materials (as applicable) within an additional sixty (60) days of expiration of such initial thirty (30) Business Day period; provided, further, with respect to any Business
Software requested by a Requesting Party hereunder that is integrated with other Software, the Parties shall discuss in good faith a reasonable deadline in lieu of the foregoing timing for delivering any such Business Software to the Requesting
Party, and the Requesting Party agrees that it shall bear all reasonable out-of-pocket costs and expenses of preparing such Software for delivery subject to the
Requesting Party’s advance approval of such costs; provided, further, to the extent the request does not constitute SpecCo Licensed Know-How, SpecCo Licensed Copyrights or Business Software
(if the Requesting Party is AgCo) or AgCo Licensed Know-How, AgCo Licensed Copyrights, AgCo Licensed Standards, or Business Software (if the Requesting Party is SpecCo), the Holding Party shall not be required
to deliver such Know-How Materials to the Requesting Party, but shall provide the Requesting Party with an explanation in reasonable detail of the basis of such determination and shall make itself and its
relevant Affiliates available to discuss in good faith with the Requesting Party. 
 (b)    For clarity, and
notwithstanding anything to the contrary, in no event shall Licensor or its Affiliates be required hereunder to provide any written, electronic, computerized, digital or other tangible or intangible media to the extent comprising, containing,
reflecting or embodying any SpecCo Licensed Know-How, AgCo Licensed Know-How, SpecCo Licensed Copyrights, AgCo Licensed Copyrights, AgCo Licensed Standards, or Business
Software to Licensee, that has already been provided to, or is in the possession of, Licensee or its Affiliates. For the avoidance of doubt, nothing in this Agreement shall be interpreted as requiring that Licensor or any of its Affiliates transfer
or grant access to tangible biological material to Licensee or any of its Affiliates. 

Section 2.11    Audit. Not more than once per year, or at any time a Party has a reasonable, good faith
belief that the other Party has materially breached this Agreement, or (to the extent with respect to this Agreement) the Umbrella Secrecy Agreement, and provides written notice to such other Party as well as detailed documentation or other evidence
of such alleged breach, upon thirty (30) days’ advance written notice, such first Party may cause an independent Third Party auditor that is reasonably acceptable to the audited Party and subject to written confidentiality obligations that
are reasonably acceptable to the audited Party to audit, during regular business hours and in a manner that complies with the reasonable building and security requirements of the audited Party and its Affiliates, the books, records and facilities of
such audited Party and its Affiliates to the extent reasonably necessary to determine such audited Party’s and its Affiliates’ compliance with this Agreement or (to the extent with respect to this Agreement) the Umbrella Secrecy Agreement.
Any audit conducted under this Section 2.11 shall not interfere unreasonably with the operations of such audited Party or any of its Affiliates. The Party requesting the audit shall pay the costs of conducting such audit;
provided that if such audit reveals a material breach of this Agreement or (to the extent with respect to this Agreement), the Umbrella Secrecy Agreement, the audited Party shall pay all such costs. Upon conclusion of the audit, the
Third Party auditor shall furnish to both Parties a report stating only its findings during such audit as to whether or not the audited Party is in compliance with this Agreement, and if such audit has revealed a breach, shall include no more
information than is reasonably necessary to provide the basis for such finding. All information learned or obtained from such audit shall be deemed Confidential Information for purposes of this Agreement.

  
 18 

 
Notwithstanding anything to the contrary in this Section, the audited Party may require that the Third Party conducting the audit pursuant to this Section 2.11 be
accompanied by the audited Party’s (and in the case of an audit of its Affiliates or Sublicensees, its Affiliate’s or its Sublicensee’s, respectively) representatives at all times during such audit. For clarity, Licensee shall cause
its Affiliates that are Sublicensees to comply with this Section 2.11. 
 ARTICLE III 

OWNERSHIP 

Section 3.1    Ownership. As between the Parties (including their respective Affiliates), (a) AgCo
acknowledges and agrees that SpecCo and its Affiliates own the SpecCo Licensed IP, the SpecCo Licensed Standards, and the Business Software licensed to AgCo under Section 2.4, (b) SpecCo acknowledges and agrees that
AgCo and its Affiliates own the AgCo Licensed IP, the AgCo Licensed Standards, and the Business Software licensed to SpecCo under Section 2.4, and (c) each Party acknowledges and agrees that (i) except to the
extent expressly provided herein, neither Party, nor its Affiliates or its Sublicensees, will acquire any ownership rights in the Licensed IP licensed to such Party hereunder, and (ii) such Party shall not, and shall cause its Affiliates and
its Sublicensees to not, represent or make any claim that they have ownership of any right, title or interest in any such Licensed IP. To the extent that a Party, its Affiliates or its Sublicensees (as applicable) is assigned or otherwise obtains
ownership of any right, title or interest in or to any Licensed IP in contravention of this Section 3.1, such Party hereby assigns, and shall cause its Affiliates and Sublicensees (as applicable) to assign, to the other
Party (or to such Affiliate or Third Party designated by such other Party in writing) all such right, title and interest. 
 ARTICLE IV

 PROSECUTION AND MAINTENANCE 

Section 4.1    Responsibility and Cooperation. 

(a)    Subject to Section 4.1(b), as between the Parties, Licensor shall have sole
responsibility (but not the obligation) for filing, prosecuting and maintaining all Patents within the Licensed IP with respect to which such Licensor or any of its Affiliates is granting a license to Licensee hereunder. Licensor shall be solely
responsible for all costs and expenses incurred in connection with such filing, prosecution and maintenance. 

(b)    If, during the Term, Licensor decides to abandon, or otherwise allow to lapse, any issued AgCo Licensed Patent (if
AgCo is the Licensor) or SpecCo Licensed Patent (if SpecCo is the Licensor) or published application therefor (the “First Abandoned Patent”), and substantially simultaneously decides to abandon, or otherwise allow to lapse all
foreign equivalents thereof and all other Patents that claim priority to such First Abandoned Patent in all jurisdictions in which such Patents are registered or applied-for (the “Abandoned Patent
Family”), Licensor shall use commercially reasonable efforts to notify Licensee of such decision at least thirty (30) days prior to any deadline for taking action to avoid abandonment (or other loss of rights) of such First Abandoned
Patent. Upon receipt of such notice, Licensee shall have the right to elect to assume responsibility for prosecution and maintenance of any or all Patents in such Abandoned Patent Family (the “Assumed Patents”) solely by providing
Licensor with 

  
 19 

 
written notice of such election within thirty (30) days (or such shorter period requested where the final deadline is in less than thirty (30) days) following such notice from Licensor,
and Licensor shall either: (i) withdraw its decision to abandon and continue prosecuting or maintaining the Assumed Patents at its expense; or (ii) assign, and hereby does assign, its entire right, title, and interest in all Assumed
Patents to Licensee at Licensee’s sole cost and expense (provided that, for clarity, Licensee shall not be required to pay any additional consideration to Licensor in exchange for such assignment, but shall be required to
reimburse Licensor for its out-of-pocket costs and expenses incurred in connection with assigning such Patents); provided that, Licensor shall not be in
breach of the foregoing if Licensor uses commercially reasonable efforts to notify Licensee of its decision to abandon (or otherwise lose rights) but inadvertently and in good faith fails to so notify Licensee. In the event that Licensor assigns any
Assumed Patents to Licensee in accordance with the foregoing clause (ii), such Patents shall no longer be (i) if the Licensor is AgCo, AgCo Licensed Patents and instead shall be SpecCo Licensed Patents, for which the AgCo Field shall be all
fields of use, or (ii) if the Licensor is SpecCo, SpecCo Licensed Patents and instead shall be AgCo Licensed Patents, for which the SpecCo Field shall be all fields of use. Notwithstanding anything to the contrary herein, in the event that any
Licensed Patent is assigned to Licensee pursuant to this (b), such Licensed Patent shall be subject to the terms and conditions of any licenses and other rights granted by or on behalf of Licensor or any of its Affiliates with respect to such
Licensed Patent prior to the date of such assignment (to the extent that such terms and conditions do not conflict with any of the terms hereof), and unless otherwise agreed in writing, the assignee Party may abandon such Patent without notice or
obligation of assignment to the other Party. 
 (c)    For clarity, Licensor’s obligations under
Section 4.1(b) do not apply to the (i) filing or validating of any national or regional applications based on any international or regional Patent applications or filings (including any PCT or EPO applications) whether
or not designated under such applications or filings, (ii) filing of any Patent application, including the filing of any divisional, continuation or
continuation-in-part application, or (iii) maintaining or prosecuting of any unpublished Patent applications. If any Licensed Patent subject to this
Section 4.1 is subject to the terms of any Contract existing as of the Effective Date to which the Licensor or any of its Affiliates is a party or otherwise bound whereby a Third Party has the right to elect to assume
responsibility for prosecution or maintenance of, or request assignment of, such Licensed Patent, and such Third Party elects not to exercise all such rights in such Licensed Patent, such Licensed Patent shall become subject to the terms of
Section 4.1(b), except if Licensor’s grant of such rights to Licensee, or Licensee’s exercise of such rights, would breach any contractual rights or obligations owed to such Third Party or any of its Affiliates.

 Section 4.2    No Additional Obligations. For clarity, this Agreement shall not obligate either Party to
disclose to the other Party, or maintain, register, monitor, prosecute, pay for or offer to pay for (including by offering remuneration to any inventors), defend, enforce or otherwise manage any Intellectual Property, except to the extent expressly
set forth herein. 
 Section 4.3    Third Party Agreements. For clarity, and notwithstanding anything to
the contrary in this Article IV, the Parties’ rights and obligations set forth in this Article IV shall be subject to the terms of any Contracts existing as of the Effective Date to which the Licensor or any of its Affiliates is a
party or otherwise bound, subject to the requirements for Licensor to notify Licensee pursuant to Section 2.7. 

  
 20 

 ARTICLE V 

ENFORCEMENT 

Section 5.1    Defense and Enforcement. 

(a)    Licensor’s Right. Subject to the remainder of this Section 5.1,
as between the Parties, Licensor shall have the sole right, but not the obligation, at its own cost and expense, to control enforcement or defense against any Third Party Infringement of the Licensed IP under which Licensor is granting a license to
Licensee hereunder (including by bringing an Action or entering into settlement discussions). 

(b)    Licensee’s Rights. In the case of any Third Party Infringement, Licensee may request
(which request Licensor may deny if Licensor reasonably determines that such Licensed IP should not be enforced or defended, and discusses its reasoning therefor with Licensee) that Licensor enforce or defend (as applicable) such Licensed IP
(including by bringing an Action or entering into settlement discussions), and if such request is granted, such enforcement or defense (as applicable) shall be controlled by Licensor at Licensee’s sole cost and expense; provided that
Licensee must approve in writing of all such costs and expenses in advance, and Licensor shall have no obligation to enforce or defend (as applicable) such Licensed IP in the event that Licensee does not approve of such costs and expenses in any
material respect. 
 (c)    Cooperation. If Licensor brings an Action with respect to any Third Party
Infringement or enters into settlement discussions with respect thereto, Licensee shall provide reasonable assistance in connection therewith, at Licensor’s request and Licensee shall be reimbursed for its reasonable out-of-pocket costs and expenses incurred in connection therewith. Licensor shall keep Licensee regularly informed of the status and progress of such enforcement or defense,
as applicable, and shall reasonably consider Licensee’s comments in connection with any Action or settlement discussions with respect thereto. Notwithstanding anything to the contrary herein, Licensee may, at its sole discretion and cost and
expense, join as a party to any such Action; provided that, if necessary for standing purposes, Licensee shall join such Action upon Licensor’s reasonable request and Licensor shall reimburse Licensee’s reasonable out-of-pocket costs and expenses incurred in connection therewith. Licensee shall have the right to be represented by counsel (which shall act in an advisory capacity only,
except for matters solely directed to Licensee) of its own choice in any such Action at its own cost and expense (subject to reimbursement of Licensee’s costs and expenses as described in, and subject to, the immediately preceding sentence).
Notwithstanding the foregoing, in the event of enforcement or defense in accordance with Section 5.1(b), Licensee shall be solely responsible for all costs and expenses incurred pursuant to this
Section 5.1(c). 
 (d)    Settlements. Notwithstanding anything to the contrary
herein, Licensor shall not, without the prior written consent (not to be unreasonably withheld, conditioned or delayed) of Licensee, settle any Third Party Infringement with respect to any Licensed IP if doing so would give rise to liability or any
other obligations of Licensee, its Affiliates or its Sublicensees for which Licensor is unwilling or unable to, or otherwise does not, provide full indemnification. 

  
 21 

 (e)    Recoveries. Any and all amounts recovered by Licensor in
any Action regarding a Third Party Infringement or settlement with respect thereto shall, unless otherwise agreed (including in an agreement in connection with obtaining consent to settlement), be allocated first to reimburse Licensor’s out-of-pocket costs and expenses incurred in connection with such Action or settlement (including its obligations to Licensee pursuant to
Section 5.1(c)) and next to the Licensee’s out-of-pocket costs and expenses incurred in connection with such Action or settlement
(including, as applicable, in accordance with Section 5.1(b) and 5.1(c)). Any and all remaining amounts recovered shall be retained by Licensor. 

(f)    Interferences, etc. Notwithstanding anything to the contrary in Article IV or this Article V,
in the event that any Third Party allegations of invalidity or unenforceability of any Patents included in the Licensed IP licensed to Licensee hereunder arise in an opposition, interference, reissue proceeding, reexamination or other patent office
proceeding, Article IV shall govern the Parties’ rights and obligations with respect thereto. 

Section 5.2    Third Party Agreements. For clarity, and notwithstanding anything to the contrary in this
Article V, the Parties’ rights and obligations set forth in this Article V shall be subject to the terms of any Contracts existing as of the Effective Date to which the Licensor or any of its Affiliates is a party or otherwise
bound, subject to the requirements for Licensor to notify Licensee pursuant to Section 2.7. 
 ARTICLE VI

 INDEMNIFICATION 

Section 6.1    Indemnification. 

(a)    Each Party (the “Indemnifying Party”) agrees to indemnify, release, defend and hold harmless the
other Party and its Affiliates and its and their directors, officers, agents, and successors (each, an “Indemnitee” and collectively, the “Indemnitees”) from and against any and all Indemnifiable Losses incurred or
suffered by any of the Indemnitees, to the extent arising out of, relating to or resulting from (a) breach by the Indemnifying Party of this Agreement; (b) if the Indemnifying Party is the Licensee, use of the Licensed IP hereunder by or
on behalf of such Party or its Sublicensees; and (c) if the Indemnifying Party is the Licensor, breach by or on behalf of Licensee, its Affiliates or its Sublicensees of any contractual rights of or contractual obligations owed to any Third
Parties with respect to the Licensed IP; provided that, prior to such breach, Licensor or any of its Affiliates is aware, and Licensee and its Affiliates are not aware, of such contractual rights or obligations, in each case (in
respect of the foregoing subsections (a) through (c)), except to the extent that such Indemnifiable Losses (i) are subject to indemnification by the other Party pursuant to this Section 6.1 or (ii) arise out
of fraud, bad faith, gross negligence or willful misconduct of the other Party or its Affiliates. 
 (b)    Except for
the entitlement to specific performance or other equitable remedy, each solely as contemplated by Section 10.12, the remedies provided in this Section 6.1 shall be deemed the sole and exclusive
remedies of the Parties with respect to the subject matter 

  
 22 

 
of this Agreement, and the Parties each hereby waive to the extent permitted by applicable Law any other remedy to which they or any of their respective Indemnitees are entitled to hereunder at
law or in equity with respect thereto. 
 Section 6.2    Indemnification Procedures. The indemnification
procedures set forth in Sections 8.5 through 8.10 of the Separation Agreement shall apply to the matters indemnified hereunder, mutatis mutandis. 

Section 6.3    Disclaimer of Representations and Warranties. EACH PARTY HEREBY ACKNOWLEDGES THAT, EXCEPT TO
THE EXTENT EXPRESSLY SET FORTH IN THE SEPARATION AGREEMENT OR IN ANY OF THE OTHER ANCILLARY AGREEMENTS, EACH OF AGCO (ON BEHALF OF ITSELF AND EACH MEMBER OF THE AGCO GROUP) AND SPECCO (ON BEHALF OF ITSELF AND EACH MEMBER OF THE SPECCO GROUP)
UNDERSTANDS AND AGREES THAT NEITHER PARTY IS REPRESENTING OR WARRANTING IN ANY WAY UNDER THIS AGREEMENT (INCLUDING WITH RESPECT TO ANY CONSENTS REQUIRED IN CONNECTION HEREWITH, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, VALIDITY, ENFORCEABILITY OR SCOPE OF THE LICENSED IP) AND EACH PARTY HEREBY EXPRESSLY DISCLAIMS ALL SUCH REPRESENTATIONS AND WARRANTIES. EXCEPT AS MAY EXPRESSLY BE SET FORTH IN THE SEPARATION
AGREEMENT OR IN ANY OTHER ANCILLARY AGREEMENT, ALL LICENSED IP IS BEING LICENSED ON AN “AS IS,” “WHERE IS,” AND “WITH ALL FAULTS” BASIS. 

Section 6.4    Limitation on Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT
(INCLUDING THIS ARTICLE VI), EXCEPT WITH RESPECT TO BREACHES OF ARTICLE VII, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT LIABILITY) OR OTHERWISE, AT LAW
OR IN EQUITY, AND “LOSSES” SHALL NOT INCLUDE ANY AMOUNTS FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES; PROVIDED THAT NOTHING HEREIN SHALL PREVENT ANY INDEMNITEE FROM BEING INDEMNIFIED PURSUANT TO THIS
ARTICLE VI FOR ALL COMPONENTS OF AWARDS AGAINST THEM IN ANY THIRD PARTY CLAIM. 
 ARTICLE VII 

CONFIDENTIALITY 

Section 7.1    Disclosure and Use Restrictions. The Parties acknowledge and agree that the Umbrella Secrecy
Agreement is hereby incorporated into this Agreement, and shall apply to the transactions contemplated by this Agreement, mutatis mutandis. For the avoidance of doubt, Licensee’s material breach of the Umbrella Secrecy Agreement with
respect to Confidential Information shall constitute a material breach of this Agreement. 

  
 23 

 ARTICLE VIII 

TERM 

Section 8.1    Term. The terms of the licenses and other grants of rights (and related obligations) under
this Agreement (the “Term”) shall remain in effect (a) to the extent with respect to the Licensed Patents and Licensed Copyrights, on a Licensed
Patent-by-Licensed Patent and Licensed Copyright-by-Licensed Copyright basis, until
expiration, invalidation or abandonment of such Licensed Patent or Licensed Copyright (as applicable), (b) to the extent with respect to any Licensed Know-How, until such Licensed Know-How no longer constitutes Confidential Information; provided that, after expiration of the Term with respect to any Licensed Know-How, the licenses granted
hereunder to such Know-How shall survive such expiration in perpetuity, and (c) with respect to Business Software and Licensed Standards, in perpetuity. 

Section 8.2    Effect of Termination. 

(a)    Accrued Rights. Expiration of this Agreement, in part or in its entirety, shall be without prejudice to any
rights which shall have accrued to the benefit of either Party prior to such expiration. 
 (b)    Survival. The
following provisions of this Agreement, together with all other provisions of this Agreement that expressly specify that they survive, shall survive expiration of this Agreement, in part or in its entirety: Articles I, III, VI, VII, IX and X and
this Section 8.2. 
 ARTICLE IX 

DISPUTE RESOLUTION 

Section 9.1    Negotiation and Arbitration. In the event of a controversy, dispute or Action between
the Parties arising out of, in connection with, or in relation to this Agreement or any of the transactions contemplated hereby, including with respect to the interpretation, performance, nonperformance, validity or breach thereof, and including any
Action based on contract, tort, statute or constitution, including the arbitrability of such controversy, dispute or Action, the procedures as set forth in Article X of the Separation Agreement shall apply, mutatis mutandis. 

ARTICLE X 

MISCELLANEOUS 

Section 10.1    Complete Agreement; Construction. This Agreement, including the Exhibits and Schedules,
together with the Separation Agreement, the Umbrella Secrecy Agreement, other Ancillary Agreements and, solely to the extent and for the limited purpose of effecting the Internal Reorganization, the Conveyancing and Assumption Instruments, shall
constitute the entire agreement between the Parties with respect to the subject matter hereof and shall supersede all previous negotiations, commitments, course of dealings and writings with respect to such subject matter. In the event of any
inconsistency between this Agreement and any Exhibit or Schedule hereto, the Exhibit or Schedule shall prevail. In the event and to the extent that there shall be a conflict between the provisions of this Agreement and the provisions

  
 24 

 
of the Separation Agreement, the terms and conditions of this Agreement shall control (except as expressly set forth in Section 12.1 of the Separation Agreement). In the event of any
inconsistency between this Agreement and the provisions of (i) any Conveyancing and Assumption Instrument or (ii) that certain Intercompany License Agreement – IB, entered into as of April 30, 2019 by and between Pioneer Hi-Bred International, Inc., E.I. du Pont de Nemours and Company, PM Taiwan, Inc., DuPont US Holding, LLC, and DuPont Industrial Biosciences USA, LLC, the terms and conditions of this Agreement shall control. 

Section 10.2    Assignment. 

(a)    Neither this Agreement nor any of the rights, interests or obligations of a Party under this Agreement shall be
assigned, in whole or in part, by operation of law or otherwise, by such Party without the prior written consent of the other Party (which consent may be granted or withheld in such other Party’s sole discretion); provided
however, that such first Party (i) may assign, in whole or in part, by operation of law or otherwise, any of the foregoing to one or more of its Affiliates and (ii) may assign, in whole or in part, by operation of law or otherwise,
any of the foregoing to the successor to all or a portion of the business or assets to which this Agreement relates; provided that, (x) the assigning Party shall promptly notify the
non-assigning Party in writing of any assignments it makes under Section 10.2(a)(ii) and (y) in either case of (i) or (ii), the party to whom this Agreement is assigned
shall agree in writing to be bound by the terms of this Agreement as if named as a “Party” hereto with respect to all or such portion of this Agreement so assigned. 

(b)    Any assignment or other disposition in violation of this Section 10.2 shall be void. No
assignment shall relieve the assigning Party of any of its obligations under this Agreement that accrued prior to such assignment unless agreed to by the non-assigning Party. 

Section 10.3    Counterparts. This Agreement may be executed and delivered (including by facsimile or other
means of electronic transmission, such as by electronic mail in “pdf” form) in more than one counterpart, all of which shall be considered one and the same agreement, each of which when executed shall be deemed to be an original, and shall
become effective when one or more such counterparts have been signed by each of the Parties and delivered to each of the Parties. 

Section 10.4    Notices. All notices and other communications to be given to any Party under this Agreement
shall be sufficiently given for all purposes hereunder if in writing and delivered by hand, courier or overnight delivery service, or five (5) days after being mailed by certified or registered mail, return receipt requested, with appropriate
postage prepaid, or electronically mailed (with a response confirming receipt), and shall be directed to the address set forth below (or at such other address for a Party as shall be specified in a notice given in accordance with this
Section 10.4): 
  

			
	To AgCo:
	
	 Corteva, Inc.
 c/o Corteva, Inc.

974 Centre Road, Building 735

	Wilmington, DE 19805
	Attn:	  	General Counsel
	Email:	  	cornel.b.fuerer@corteva.com

  
 25 

			
	
	with a copy (which shall not constitute notice) to:
	
	Skadden, Arps, Slate, Meagher & Flom LLP
	Four Times Square
	New York, NY 10036
	Attention:	  	Brandon Van Dyke, Esq.
	Email:	  	Brandon.VanDyke@skadden.com
	Facsimile:	  	(917) 777-3743
	
	To SpecCo:
	
	 DowDuPont, Inc.
 c/o DuPont de
Nemours, Inc.
 974 Centre Road, Building 730

	Wilmington, DE 19805
	Attn: General Counsel
	Email: Erik.T.Hoover@dupont.com
	
	with a copy (which shall not constitute notice) to:
	
	Skadden, Arps, Slate, Meagher & Flom LLP
	Four Times Square
	New York, NY 10036
	Attention:	  	Brandon Van Dyke, Esq.
	Email:	  	Brandon.VanDyke@skadden.com
		
	Facsimile:	  	(917) 777-3743

 Section 10.5    Waivers. Any provision of this Agreement may be waived, if
and only if, such waiver is in writing and signed by the Party against whom the waiver is to be effective. Notwithstanding the foregoing, no failure to exercise and no delay in exercising, on the part of any Party, any right, remedy, power or
privilege hereunder shall operate as a waiver hereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or
privilege. Any consent required or permitted to be given by any Party to any other Party under this Agreement shall be in writing and signed by the Party giving such consent and shall be effective only against such Party (and the members of its
Group). 
 Section 10.6    Amendments. This Agreement may not be modified or amended except by an agreement
in writing signed by each of the Parties. 

  
 26 

 Section 10.7    Affiliates. Each of the Parties shall cause
to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth herein to be performed by any Affiliate of such Party. 

Section 10.8    Third Party Beneficiaries. Except as provided in Article VI relating to Indemnitees,
this Agreement is solely for the benefit of, and is only enforceable by, the Parties and their permitted successors and assigns and should not be deemed to confer upon Third Parties any remedy, benefit, claim, liability, reimbursement, claim of
Action or other right of any nature whatsoever, in excess of those existing without reference to this Agreement. 

Section 10.9    Title and Headings. Titles and headings to sections herein are inserted for the convenience
of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

Section 10.10    Exhibits and Schedules. The Exhibits and Schedules shall be construed with and as an
integral part of this Agreement to the same extent as if the same had been set forth verbatim herein. 

Section 10.11    Governing Law. This Agreement and any dispute arising out of, in connection with or relating
to this Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to the conflicts of laws principles thereof. 

Section 10.12    Specific Performance. The Parties acknowledge and agree that irreparable harm would occur in
the event that the Parties do not perform any provision of this Agreement in accordance with its specific terms or otherwise breach this Agreement and the remedies at law for any breach or threatened breach of this Agreement, including monetary
damages, are inadequate compensation for any such non-performance or breach. Accordingly, in the event of any actual or threatened default in or breach of, any of the terms, conditions and provisions of this
Agreement, the Parties agree that the Party or Parties to this Agreement who are or are to be thereby aggrieved shall, subject and pursuant to the terms of this Article X (including for the avoidance of doubt, after compliance with all notice
and negotiation provisions herein), have the right to specific performance and injunctive or other equitable relief of its or their rights under this Agreement in addition to any and all other rights and remedies at law or in equity, and all such
rights and remedies shall be cumulative. The Parties agree that any defense in any action for specific performance that a remedy at law would be adequate is hereby waived, and that any requirements for the securing or posting of any bond with such
remedy are hereby waived. 
 Section 10.13    Severability. In the event any one or more of the provisions
contained in this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and therein shall not in any way be affected or impaired thereby. The
Parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid, legal and enforceable provisions, the economic effect of which comes as close as possible to that of the invalid, illegal or
unenforceable provisions. 

  
 27 

 Section 10.14    No Duplication; No Double Recovery.
Nothing in this Agreement is intended to confer to or impose upon any Party a duplicative right, entitlement, obligation or recovery with respect to any matter arising out of the same facts and circumstances. 

Section 10.15    Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by a
Licensor are, and will otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code, licenses of rights to “intellectual property” as defined under Section 101 of the United States Bankruptcy
Code regardless of the form or type of intellectual property under or to which such rights and licenses are granted and regardless of whether the intellectual property is registered in or otherwise recognized by or applicable to the United States of
America or any other country or jurisdiction. The Parties agree that each Licensee will retain and may fully exercise all of their rights and elections under the United States Bankruptcy Code. The Parties further agree that, in the event of the
commencement of a bankruptcy proceeding by or against a Party under the United States Bankruptcy Code, the Party hereto that is not a party to such proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) any
such intellectual property and all embodiments of such intellectual property, which, if not already in the non-subject Party’s possession, will be promptly delivered to it (a) upon any such
commencement of a bankruptcy proceeding upon the non-subject Party’s written request therefore, unless the Party subject to such proceeding continues to perform all of its obligations under this Agreement
or (b) if not delivered under clause (a) above, following the rejection of this Agreement by or on behalf of the Party subject to such proceeding upon written request therefore by the non-subject
Party. 
 * * * * * 

[End of page left intentionally blank] 

  
 28 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day
and year first above written. 
  

									
	SPECIALTY PRODUCTS N&H, INC.	 		 	PM TAIWAN, INC.
			
	              /s/ Michael P.
Heffernan
	 		 	              /s/ Michael P.
Heffernan

	 Name:
 Title:
	 	 Michael P. Heffernan
 President
	 		 	 Name:
 Title:
	 	 Michael P. Heffernan
 President

			
	DUPONT ELECTRONICS, INC.	 		 	DUPONT SAFETY & CONSTRUCTION, INC.
			
	              /s/ Michael P.
Heffernan
	 		 	              /s/ Michael P.
Heffernan

	 Name:
 Title:
	 	 Michael P. Heffernan
 President
	 		 	 Name:
 Title:
	 	 Michael P. Heffernan
 President

			
	DUPONT POLYMERS, INC.	 		 	DUPONT US HOLDING LLC
			
	              /s/ Michael P.
Heffernan
	 		 	              /s/ Michael P.
Heffernan

	 Name:
 Title:
	 	 Michael P. Heffernan
 President
	 		 	 Name:
 Title:
	 	 Michael P. Heffernan
 President

			
	DUPONT INDUSTRIAL BIOSCIENCES USA, LLC	 		 	DOWDUPONT INC.
			
	              /s/ Jessica
Sinnott
	 		 	              /s/ Erik T.
Hoover

	 Name:
 Title:
	 	 Jessica Sinnott
 Associate General Counsel
– IP
	 		 	 Name:
 Title:
	 	 Erik T. Hoover
 General Counsel &
Secretary

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day
and year first above written. 
  

									
	CORTEVA, INC.	 		 	PIONEER HI-BRED INTERNATIONAL, INC.
			
	              /s/ Cornel B.
Fuerer
	 		 	              /s/ Cornel B.
Fuerer

	Name:	 	Cornel B. Fuerer	 		 	Name:	 	Cornel B. Fuerer
	Title:	 	General Counsel & Secretary	 		 	Title:	 	General Counsel & Secretary
				
	E.I. DU PONT DE NEMOURS AND COMPANY	 		 		 	
				
	              /s/ Cornel B.
Fuerer
	 		 		 	
	Name:	 	Cornel B. Fuerer	 		 		 	
	Title:	 	General Counsel & Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]